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ABSTRACT

VITAMIN D PLUS CALCIUM SUPPLEMENTATION AMONG POSTMENOPAUSAL
WOMEN: EFFECT ON RISK OF HEART FAILURE IN THE
WOMEN'S HEALTH INITIATIVE
STUDY
Macarius Mwinisungee Donneyong
04/16/2013

This study evaluates the impact of vitamin D plus calcium supplementation as a
primary intervention for heart failure (HF) prevention and examines whether preexisting
conditions that are precursors of HF modify this relationship in a large cohort of
postmenopausal women.
Analysis included 35,113 postmenopausal women (17,595 intervention, 17,518
control) aged 50 to 81 years enrolled in the randomized trial of vitamin D plus calcium
(CaD) in the Women’s Health Initiative (WHI) study. The women in this analysis cohort
were free of HF at the time of randomization and during the first year of the trial. The
intervention consisted of 1,000 mg/day of calcium and 400 IU/day of vitamin D3.
vi

Incident HF cases over an average follow-up period of 7.13 (standard deviation, 1.33)
years were identified from hospital discharge records and adjudicated by a physician
committee. An intention-to-treat (ITT) approach was used to estimate hazard ratios (HR)
and 95% confidence (CI) intervals from multivariable Cox Proportional Hazards
regression models. A formal test of interaction between the intervention and a composite
of risk factors that predispose towards the development of HF (hypertension,
cardiovascular diseases, coronary heart diseases/events, and diabetes) and define ‘Stage
A’ HF was performed.
CaD was associated with a non-significant 7% reduced risk of heart failure (HR =
0.92; 95% CI, 0.79 –1.06) in a multivariable model in the overall study cohort. However,
CaD was associated with a clinically and statistically significantly lower risk (35%) of
HF (HR = 0.65; 95% CI, 0.46 – 0.92; P = 0.01) among participants who were free of
Stage A HF but neither a clinically nor a statistically significant effect among those with
Stage A HF (HR = 1.02; 95% CI, 0.85 – 1.21; P = 0.87). Moreover, these effect
estimates were not modified by baseline total (diet and supplements) vitamin D and
calcium intake and persisted in a per-protocol and other sensitivity analyses.
These findings suggest that a low cost daily supplementation with vitamin D plus
calcium may be an effective primary prevention strategy in postmenopausal without
major cardiovascular precursors of HF but of little value in those with these risk factors.
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INTRODUCTION
Heart failure (HF) is a major public health problem with enormous health care
cost, mortality, and functional limitation (1). Currently, about 5.8 million adult
Americans live with HF, and half of this population will die within five years of
diagnosis (2, 3). The prevalence and mortality rate of HF are likely to continue because
HF carries a lifetime risk of 20% after 40 years of age (4). Given the high associated
healthcare cost and burden on HF survivors, it is a high priority to identify interventions
for HF prevention. Some have suggested that dietary supplementation with vitamin D
may be a potential inexpensive primary prevention measure that can be explored to
mitigate this epidemic.
The role of vitamin D in HF pathogenesis in humans is not well established.
Indeed there are few published studies designed with the ability to test a causal
hypothesis. However, several observational studies have examined associations between
cardiometabolic outcomes, including HF, and vitamin D deficiency/insufficiency. While
several of these studies suggest an association between low 25(OH) vitamin D levels and
increased risk of cardiometabolic outcomes, some inconsistencies still exist (5-9). Animal
models, however, provide compelling evidence to demonstrate a plausible
pathophysiological role of vitamin D in the etiology of HF (10-12). Hence, one of the
existing knowledge gaps on the role of vitamin D in HF is whether a protective effect can
1

be demonstrated in humans. To bridge this gap, it is imperative to analyze data from a
randomized controlled trial (RCT) of vitamin D among a primary prevention cohort free
of HF at baseline. Data from the Women’s Health Initiative (WHI) clinical trial of
combined vitamin D and calcium is an ideal resource for this type of analysis.
While results from RCTs are inconsistent for the associations between some
cardiovascular diseases (CVDs) and vitamin D alone, or combined with calcium, data
from observational longitudinal studies tend to be more consistent on reporting inverse
associations (5, 6, 8, 9). To our knowledge, however, none of these RCTs included CVD
as a primary pre-specified outcome. Among HF patients, supplementation with vitamin
D has been observed to have modest effects on some prognostic outcomes such as
improved ventricular function and N-terminal fragment brain natriuretic peptide (NTproBNP) levels (8). Data on vitamin D supplementation among chronic kidney disease
patients provides vital information about the plausible pathophysiological mechanism by
which low vitamin D may initiate cardiac malfunctioning (13-17). The evidence from
these studies, albeit modest, has stimulated intense interest in assessing the possible
benefits of vitamin D in HF pathogenesis.
This dissertation investigates the effect of combined supplementation with
vitamin D and calcium as a primary HF prevention among postmenopausal women. It
also examines whether the composite of preexisting conditions (e.g., hypertension,
cardiovascular diseases, coronary heart diseases/events, and diabetes) that are precursors
of HF modify the effect of vitamin D plus calcium supplementation on HF incidence. We
hypothesize that vitamin D plus calcium supplementation will reduce HF incidence in the
2

overall population; this risk reduction will be stronger in the group of women with these
preexisting HF precursors than in those free of these precursors. The American College
of Cardiology (ACC) classifies individuals with any of these risk factors (hypertension,
cardiovascular diseases, coronary heart diseases/events, and diabetes) who have not yet
developed structural abnormalities like left ventricular dysfunction or hypertrophy or
geometric chamber distortion as ‘Stage A’ heart failure and those who demonstrate any
of these structural abnormalities as ‘Stage B’. While Stages A and B heart failure are not
HF per se, these designations enable healthcare providers to identify individuals at the
greatest risk of HF for early interventions (18). In the general female population between
the ages of 40 – 89 years, hypertension, diabetes, and CVDs are associated with
population attributable risks (for HF) of 59%, 12%, and 26%, respectively (19).
Interestingly, these precursors of HF have also been found to be inversely correlated with
serum vitamin D levels (5-9).
In line with the American Heart Association (AHA)/American College of
Cardiology (ACC) recommendation for targeting HF interventions in those with these
risk factors and classified as stage A or B, it is work investigating whether
supplementation with vitamin D plus calcium could be an effective intervention. Such an
inexpensive intervention, if effective, could be a novel public health strategy to mitigate
the unabated rise of healthcare costs, mortality, functional limitation, and impairment of
quality of life associated with HF.

3

CHAPTER 1
BACKGROUND AND SIGNIFICANCE OF HEART FAILURE AND VITAMIN D
DEFICIENCY AMONG ADULTS
1.1 Heart Failure
1.1.1 Definition and Classification of Heart Failure
There is no one specific definition of HF owing to lack of consensus on diagnostic
criteria. Several definitions have been proposed over the past decades. However, the
American Heart Association and American College of Cardiology (AHA/ACC) defined
heart failure (ICD-10: 150) as “a complex clinical syndrome that can result from any
structural or functional cardiac disorder that impairs the ability of the ventricle to fill with
or eject blood” (20). This definition is more comprehensive than previous ones which
were limited to either the symptoms alone or physical signs of fluid retention alone (2123).
Fishberg first reported – over 70 years ago – the existence of two forms of heart
failure (24). These were later termed diastolic and systolic heart failure. While the
definition of diastolic heart failure (DHF) has been controversial, Zile and Brutsaert
(2002) recently defined DHF as a condition in which the “ventricular chamber is unable
4

to accept an adequate volume of blood during diastole at normal diastolic pressures and at
volumes sufficient to maintain an appropriate stroke volume” (25). In contrast, systolic
heart failure (SHF) was defined by Braunwald (1980) as “‘a pathophysiological state in
which an abnormality of cardiac function is responsible for the failure of the heart to
pump blood at a rate commensurate with the requirements of the metabolizing tissues”
(26). Both definitions, however, only describe structural and functional abnormalities
(27).
HF has subsequently been defined by the left ventricular ejection fraction (LVEF)
which is the ratio of end systolic volume (blood ejected during systole) to end-diastolic
volume (blood in the ventricle at the end of diastole). Heart failure with preserved left
ventricular ejection fraction (HPLVEF) and heart failure without preserved left
ventricular ejection fraction are the current terminologies. HPLVEF occurs when a higher
filling pressure is required to achieve normal end-diastolic volume in the left ventricle
even though the “normal” pumping function of the left ventricle is maintained (28, 29,
30). What constitutes a preserved LVEF is a contentious issue in the scientific
community. While there is no consensus on the threshold for LVEF to distinguish the two
forms of HF, LVEF greater than 40% to 50% is widely referred to as preserved (21, 31,
32). Distinguishing HF based on LVEF has important epidemiological and great clinical
importance as discussed in subsequent sections.
1.1.2 Assessment of HF in Epidemiologic Studies
This section reviews existing HF assessment methods in epidemiologic studies.
The most commonly used clinical diagnostic criteria are those used in the Framingham
5

Heart Study (FHS), the European Society of Cardiology (ESC), and the Boston clinical
diagnostic criteria of heart failure (21, 33, 34). The FHS establishes definite heart failure
diagnoses based on two major or one major and two minor criteria assessed by physical
examination, clinical tests, and chest X-ray (34). The ESC criteria involve tests based on
electrocardiogram, chest X-ray, and laboratory results on total blood count, serum
electrolytes and creatinine, estimated glomerular filtration rate, glucose, liver function,
and urinalysis (21). The Boston criteria classifies patients as possible, definite, or
unlikely heart failure based on history of dyspnea, physical examination of heart rate,
jugular-venous pressure, and lung function, and a chest X-ray (33). Detailed description
of each of these criteria can be found in the appendix.
Heart failure assessment in primary data collection
There is a lack of consensus on the HF diagnostic criteria with the least
misclassification bias – the criterion with the highest diagnostic validity (35). While this
is a matter of concern, few studies have evaluated and compared, head-to-head, which of
the existing criteria should be the most preferable for diagnosing HF in the community.
Bari et. al. (2004) conducted a comparative validation study of established criteria
for HF ascertainment among 553 elderly community dwellers of mean age 73 ± 0.3years
(36). The FHS, Boston, and ESC criteria were compared on the prevalence and diagnostic
concordance, construct validity, and predictive validity of heart failure incidence. The
agreement between these criteria ranged from very poor (k = 0.05) to moderate (k = 0.59)
even though the prevalences based on these criteria were similar for Framingham
(11.9%), Boston (10.7%), and ESC (9.0%); the prevalence was much higher (20.8%)
6

when assessed by the Gothenberg criteria. However, the Boston and Framingham criteria
were superior over Gothenberg and ESC when discriminating between HF and non-HF in
terms of the construct validity. Components of the construct validity included
abnormalities in cardiac structure and function (left ventricular mass index, left
ventricular ejection fraction, and left atrial systolic dimension), and global functional
status (lower extremity mobility disability, 6-minute walk test, and summary performance
score). In terms of predictive validity the Boston criteria were superior over the rest;
components of the predictive validity were cardiovascular mortality, incident basic
activities of daily living disability, and HF-related hospitalizations (36). This study, Bari
et. al. (2004), highlights the inconsistency in epidemiologic results from population-based
studies. Even though the study suggests the Boston criteria has the best construct validity
most accurately predicts cardiovascular death, disability, and hospitalization, this is by no
means a final verdict on which method should the most preferable. The relatively small
sample (N = 553) and old population (mean age, 73.0 ± 0.3 years) limits the application
of this study.
In the other study, Schellenbaum et. al. (2004) compared the incidence and
survival of HF among a cohort of 875 hospitalized HF patients – sampled from the
Cardiovascular Heart Study (CHS) population - after a HF onset as defined by the FHS or
CHS central adjudication criteria, or both (37). While there were no observed differences
for mortality (HRs 0.87 vs 0.89) between these criteria, the FHS criteria identified as
twice as many incident HF cases (n = 140) as the CHS criteria (n = 71). This suggests the
CHS centrally adjudicated process might be more conservative than the FHS; the FHS
criterion was not complemented with central adjudication process by a panel of
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physicians. Likely, there would have been relatively higher misclassification of incident
cases identified by the FHS approach. The shortfalls of this study were based on the use
of death as a HF end-point since little differences could be detected in this elderly (mean
age of 80 yrs) sample. The comparison was also weakened by the significantly larger
proportion of missing data reported for the FHS criteria. Notwithstanding these
shortcomings, the study highlights the importance of central adjudication of HF cases for
epidemiologic studies. In summary, there is no current “gold standard” for identifying
incident HF cases with minimum misclassification bias, central adjudication by a
committee is essential for assessing HF in epidemiological studies (37-40).
Heart failure assessment in secondary data collection - hospital discharge diagnosis
Epidemiological studies often utilize hospital discharge data for estimating the incidence
and secular trends of heart failure because of their relative ease of accessibility and lower
cost to the investigator. However, hospital discharge data are influenced by
reimbursement codes as well as inconsistencies in coding practices (41). Heckbert et. al.
(2004) reported moderate agreement (k = 0.56, 095% CI:0.53 – 0.59) between HF cases
identified by hospital discharged codes and by a local adjudication committee of the WHI
study based on data from 34,016 participants with reported cardiovascular endpoints (42).
In another study, Schellenbaum et. al. (2006) compared HF incidence rates between
hospital discharge diagnosis (ICD-9 codes: 428, 997.1, 425, 402.01, 402.11, 402.91, and
398.91.) and adjudication based on data from the Cardiovascular Health Study and found
that the incidence of HF was higher with the hospital discharge criterion compared to the
central adjudication criterion, 24.6 vs 17.1 per person-years (38). In summary, there is no
current “gold standard” for identifying incident HF cases with minimum misclassification
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bias, central adjudication by a committee is essential for population studies because this
method has a relatively higher specificity (37-40, 42).
1.2 Epidemiology
HF continues to be a major public health concern even though the incidence of
heart failure (HF) appears to have plateaued over the last decade owing to decline of
major determinants such as ischemic heart disease and control of hypertension (43). With
a current estimated prevalence of 2 – 3% in the US, this pool of 5.8 million HF patients is
likely to grow as a result of rapidly aging population and improved management that
prolongs survival (43). Worldwide, it is estimated that 23 million individuals are affected
with HF (44). Consequently, HF will continue to exact a large toll on public health
resources and pose a major health burden on individuals and their families.
The current prevalence and incidence estimates might be an under-estimation of
the real impact of HF because of lack of consensus on the HF assessment criteria at the
population level. Additionally, reported prevalence and incidence rates among females
and the elderly are not consistent with the national figures. Under-reporting and poor
diagnoses are also likely sources of under-estimation of HF at worldwide level.
1.2.1 General Population
Prevalence
The American Heart Association’s 2011 update on Heart diseases and Stroke
indicated about 5.8 million (2.42%) adult Americans reported they have been diagnosed
with HF based on data from NHANES (2). The age-adjusted self-reported prevalence of a
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relatively younger (≥18 years) population of the National Health Interview Survey was
1.2% in 1999 (45). In the Olmsted County (MN) study, 2.2% of the population (n =
2,024) aged 45 years and above were assessed to be living with HF based on the FHS
criteria (46). However in an older population of Medicare beneficiaries aged 65 years and
above, the prevalence of HF in 2003 was 12.1%; diagnostic records indicated the
prevalence was higher in men (12.9%) than women (11.5%) (47). In the Rotterdam study,
the prevalence, as assessed by the ESC method, was 7.0% among a population with an
average age of 74.5 years. In these and other studies, the prevalence increased with older
age and with male gender.
Incidence
The incidence of HF is reported to range from 2 to 5 per 1000 person-years
depending on the method of HF case ascertainment and population. After an average
follow-up of 5.5 years of an elderly population (mean age 73.5 years) in the CHS, the
incidence of HF was 19.3/1,000 person-years. Again, as for prevalence, the incidence rate
rose with increasing age and male sex (48). In the FHS, the incidence was slightly higher
in men (5.64/1000 person-years) which remained unchanged between 1950 – 1999
compared to females (3.27/1000 person-years) who experienced a decline of about 31 –
40% during the same period (49). In the Olmsted County, MN study, there was no
temporal decline in HF incidence. Again, the incidence was relatively higher in males
compared to females, 3.78 vs 2.89 per 1000 person-years (3). There is insufficient
evidence to suggest there is or might soon be a decline in HF incidence in spite of these
data suggesting a plateauing of incidence rates.
10

Mortality
The five-year HF mortality is still high even though there has been a decline in
the last three devades (2, 3, 49). HF tends to have poor survival prognosis after diagnosis
– mortality increases with post-diagnostic time. In 2007, 11% of deaths had HF
mentioned on the certificate, of which every 1 out of 5 deaths was due to HF. About 60%
of these deaths occurred in females (2). These national data are based on mortality due to
HF and do not clarify survival time after onset of HF (49). Reviews by Hsich et. al (2009)
and Shah et. al. (2009) suggested females have better five-year survival compared to
males (50, 51). However, these sex differences tend to narrow when investigated in older
age populations and there is no difference in the overall survival trends.
Data from the FHS showed 30-day, one-year, and five-year mortality rates as
11.5%, 26%, and 52% respectively for the period between 1990 and 1999. The 5-year
mortality rate declined by 16% and 21% from 1950 – 1990 for both males and females
respectively (49). This has been confirmed by data from the Olmsted County, MN study
where an overall decline of 16% in HF 5-year mortality was observed between 1979 and
2000. In this population however, there were age and sex differences in the decline of
mortality. Improvement in survival was highest among younger ages (< 70 years) for
both sexes but remained higher among males. In contrast, improvement in survival for
older males was less, compared to younger males while older females did not improve in
survival over time (3). These results have been corroborated in a study by Barker et. al.
(2006) among a well defined older population (≥ 65 years) based on administrative data
(52). This retrospective cohort study suggested while HF incidence increased between
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1970s and 1990s, the overall five-year survival for the same period improved, with males
experiencing higher incidence and improved survival compared to females (52).
The five-year age-adjusted mortality due to HF declined over the past 4 – 5
decades with little or no differences between the sexes. This trend was consistent in all
the data reviewed in spite of population structure differences between these data. This
contrasts with the higher HF incidence figures associated with males, as presented in the
previous section. With equity in the survival rates between the sexes, it suggests more
males than females are surviving with HF owing to some biological and therapeutic
differences.
1.2.2 Heart Failure among Women
While the studies reviewed suggest the incidence of HF among males may be
higher than among females, they failed to distinguish between systolic HF and heart
failure with preserved left ventricular ejection fraction (HPLVEF). More females than
male HF patients tend to have HPLVEF. The observed HPLVEF prevalence difference
between males and females is crucial for interpreting epidemiologic data of HF in the
general population.
1.2.3 Heart Failure with Preserved Ejection Fraction
Owan and Redfield (2005) reported the prevalence of HPLVEF among overt HF
patients aged 25 years and above to range between 40 – 71% (53). The prevalence of
HPLVEF increased over a fifteen-year period among 6,076 patients discharged with HF.
In this study, by Owan et. al. (2006), HF was validated using the FHS and clinical
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criterion (attending physician’s recorded diagnosis) with HPLVEF defined as HF with
LVEF ≥ 50% (54).
Data on mortality differences between HF with reduced ejection fraction and
HPLVEF have been inconsistent. In their review of the current epidemiologic data on
mortality associated with HF diagnosis with reduced and preserved ejection fractions,
Owan and Redfield (2005) could not find sufficient evidence supporting better survival
for either form of HF (53). However, among the CHS cohort, the population attributable
risk of mortality was higher for those with impaired left ventricular function, EF <45%
(7.5%) compared to those with normal ventricular function, EF >=55% (5.9%) and may
partly explain why females have higher HF mortality (48). It should be observed that the
epidemiologic studies reviewed in this publication used all-cause mortality as their
outcome instead of CVD mortality or, more precisely, HF-specific mortality, which
would have been more informative on the pathophysiological differences between the
two forms of HF. However, Owan et. al. (2006) reported HPLVEF (EF ≥ 50%) to be
associated with slightly lower risk of mortality (HR = 0.96; 95%CI: 0.92 – 0.99)
compared to those with reduced ejection fraction (EF ≤ 50%). In contrast, when secular
trends in survival were investigated, HF with reduced ejection fraction was associated
with improved survival compared to HPLVEF (54). This paradoxical finding may be
attributable to the lack of existing proven effective therapies for HPLVEF (35, 54).
1.3 VITAMIN D
Vitamin D is a curious vitamin; it mimics the action of a hormone in humans and
is the only vitamin that is synthesized in the body with exposure to solar radiation.
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Historically, vitamin D was discovered as a result of high prevalence of rickets in
children during the industrial revolution in northern Europe. This condition was
recognized to be a result of reduced sun exposure owing to high air pollution. These
events spurred the search for a cure of rickets and the eventual discovery of vitamin D
(55).
1.3.1 Source and Synthesis of Vitamin D
When it was discovered humans could synthesize vitamin D from the sun’s
radiation, efforts were made to artificially produce vitamin D. Ultra-violet (UV) lamps
were used for treating rickets both in humans and animals. Subsequently, foods,
especially milk, were fortified with vitamin D through irradiation. Currently, the
fortification of foods with vitamin D has been expanded to include fruit juices, cereals,
and dairy products. However, there are only a few naturally occurring sources of vitamin
D. Sea foods, especially oily fish like wild salmon have abundant reserves of vitamin D.
And now, vitamin D supplements are readily available. Vitamin D2 and D2 are the
commercially available vitamin D supplements. Vitamin D 2, also known as
ergocalciferol, is derived from yeast/fungus while D3, also known as colecalciferol is
synthesized from animal sources through a process similar to how humans synthesize
vitamin D from sunlight (56).
Humans and other land vertebrates have abundant concentrations of 7dehydrocholesterol, a precursor of cholesterol, in their skin. Figure 1 illustrates a
schematic synthesis of vitamin D from 7-dehydrocholesterol in the skin through exposure
to UV radiation as well as from diet/supplements (57). When the skin surface is exposed
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to UV-B from the sun, 7-dehydrocholesterol undergoes chemical transformation to
become pre-vitamin D3. Pre-vitamin D3 is highly unstable and undergoes further
transformation (rearrangements of it’s double bonds to be precise) to produce vitamin D3.
Vitamin D3 then binds to a vitamin D binding protein in the epidermal bed and is
transported to the liver for metabolism. Vitamin D 2 and D3 can also be acquired from diet
and nutritional supplements. All these forms of exogenous vitamin D are metabolized in
the liver to form 25(OH)D, an intermediate metabolite of vitamin D which is used as a
vitamin D biomarker. When transported to the kidneys, the enzyme 25-hydroxyvitamin
D-1α-hydroxylase converts 25(OH)D to its active metabolic form, 1,25dihydroxyvitamin D (1,25[OH]2D) (58-60).
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Figure 1. Schematic representation of vitamin D synthesis in humans.
Reference: Hajjar V, Depta JP, Mountis MM. Q: Does vitamin D deficiency play a role in
the pathogenesis of chronic heart failure? Do supplements improve survival? Cleve Clin J
Med 2010;77(5):290-3.

1.3.2 Assessment of Vitamin D Status
Vitamin D status in populations is based on serum concentrations of the vitamin
D biomarker, 25(OH)D. In their guidelines for vitamin D deficiency, Holick et. al. (2011)
recommended against screening for vitamin D deficiency based on the active metabolic
form, 1,25(OH)2D, because its concentrations are regulated by plasma parathyroid
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hormones (PTH) and intestinal calcium and phosphorus levels (58-61). Instead, 25(OH)D
levels are preferred for screening populations for vitamin D deficiency. Alternatively,
vitamin D status in populations can be measured by exogenous vitamin D intake. This
method, based on data from self-reported dietary and supplement intake, is less precise
than that based on measured serum levels of endogenous 25(OH)D levels. Serum
25(OH)D levels reflect the amount of vitamin D ingested from both diet and
supplements, as well as that synthesized endogenously. However, in populations where
the sun is the major source of vitamin D, vitamin D status assessment based on serum
25(OH)D levels is not an accurate method.
Firstly, serum 25(OH)D concentrations are greatly influenced by seasonal
variation in sun exposure. As expected, individual and population-based 25(OH)D levels
reach their peak and nadir in the summer and winter months respectively (62). This
makes baseline or one time measurements of 25(OH)D inaccurate for estimating the
vitamin D status of subjects (63). This shortfall is corrected in population based studies
by statistically controlling for season of blood draw (63). Additionally, validation of
serum 25(OH)D levels can be conducted by taking serial measurements that span all
seasons.
Second, 25(OH)D concentrations are highly variable because 25(OH)D has a
relatively short circulation half-life (about 3 weeks) (64, 65). This may reduce its
predictive value for estimating the relationship between vitamin D status and diseases. As
suggested above, taking serial measurements of subjects in longitudinal studies is one
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way to overcome this flaw. However, it will time consuming and expensive to routinely
screen patients for their vitamin D status in large population-based studies.
Serum 25(OH)D measurement is still the preferred method for estimating vitamin
D status in epidemiological studies in spite of the drawbacks mentioned above. Both
vitamin D3 (cholecalciferol) and D2 (ergocalciferol) and the active metabolite of vitamin
D, 1,25(OH)2D, have shorter circulation half-lives compared to 25(OH)D (66, 67)
making them more difficult to assay. Moreover, they don’t reflect total vitamin D from
both endogenous and exogenous sources. Total vitamin D intake has worse reliability
compared to 25(OH)D and the other biomarkers because this method is subject to recall
biases of all foods and the quantity eaten in the past. Also, the amount of vitamin D
endogenously synthesized is missed, which leads to underestimation of vitamin D status
because sun exposure is still a major source of vitamin D for both young and old
community dwelling adults (68). In addition, the metabolism of total vitamin D intake
from diet and supplements is affected by race, age, sun exposure, obesity, physical
activity, and region of residence (69, 70).
Hence in assessing vitamin D status of populations in epidemiologic studies, it is
advisable to incorporate both total vitamin D intake and amount of sun exposure in the
region of residence together with the preferred biomarker of vitamin D status, 25(OH)D
(63).
1.3.3 Vitamin D Insufficiency: Issues on Definition and Prevalence
The definition of adult vitamin D deficiency has been debated over the years in
the scientific community. This debate has been partly fueled by the emergence of non18

musculoskeletal functions of vitamin D. However, a threshold of serum vitamin D
(25[OH]D) levels less than 20 ng/mL (50 nmol/L) is widely accepted as indication of
adult vitamin D insufficiency (71). Although some have defined vitamin D insufficiency
25(OH)D levels as <30 ng/mL, this definition has been challenged by the IOM (60, 61,
72-74). Definitions used by different groups have been based on evidence from studies
that reported absorption of intestinal calcium is optimized at 25(OH)D levels above 32
ng/mL in postmenopausal women and by evidence that adult parathyroid hormone (PTH)
concentrations reach their lowest point at 25(OH)D levels between 30 ng/mL and 40
ng/mL (75-78). While these vitamin D concentration thresholds are widely employed for
screening and surveillance purposes, investigators often define their own cut-off values in
studying associations between vitamin D status and health outcomes.
Based on data from NHANES (2001-2004), 6% of the US population aged 12
years and older had severe low vitamin D status, 25(OH)D < 10ng/mL (79).
Approximately three-quarters of the population, 71 % (95%CI: 68-73), had 25(OH)D
concentrations between 10 ng/mL and 30 ng/mL. On average, non-Hispanic whites had
relatively higher mean 25(OH)D levels (≈ 26 ng/mL) compared to non-Hispanic blacks,
≈ 15 ng/mL. On the other hand, there were no observed differences in the mean 25(OH)D
levels (≈ 24 ng/mL) between the sexes. While there were no age-related differences in
mean 25(OH)D levels, age was inversely related to 25(OH)D concentrations among nonHispanic whites but not in non-Hispanic blacks.
Recent analysis of the 2005 – 2006 NHANES data restricted to participants aged
20 years and above (N=4,495) reported 41.6% of this population had vitamin D
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insufficiency (25[OH]D < 20 ng/mL) with even higher rates among Blacks (82.1%) and
Hispanics (62.9%). While there were no observed significant differences in 25(OH)D
between different age groups, the prevalence of vitamin D insufficiency was highest
among 55 – 59 years (49%) and 60 – 65 years (47%) (80). While both analyses of two
separate NHANES datasets concluded the prevalence of vitamin D deficiency is high in
the US, the prevalence is likely to be much higher because populations living in the
northern latitudes of the US were not sampled during winter months.
It is not very clear why these disparities in 25(OH)D occurred, but Ginde et. al.
(2009) posited the difference could be as a result of varying time spent indoors. Their
analysis of the NHANES data however did not explore differences in duration of outdoor
activities between the sexes and age categories. The explanation given by Ginde et. al.
starkly contrasts with the results of Scragg and Camargo (2008) who reported younger
adults in the NHANES (1988 – 1994) data reported doing more outdoor physical activity
than older adults. In their analysis, mean 25(OH)D levels decreased significantly with
increasing age groups of 20 – 39 years, 40 – 49 years and ≥ 60 years (81). The higher
prevalence of vitamin D supplements consumption among older age groups has been
proposed by Tangpricha et. al. (2002) as a possibility for this 25(OH)D-age relationship
(82).
In Europe the prevalence of 25(OH)D levels less than 10 ng/mL ranges between 2
– 30% among adults with lower rates recorded, surprisingly, in Northern Europe (83, 84).
While the wide variation might be partly due to non-uniformity in assay methods, multicenter studies in Europe where 25(OH)D levels were assayed in a single laboratory,
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higher serum 25(OH)D levels were still observed in Northern latitudes. This unexpected
distribution of 25(OH)D concentrations between Northern and Southern European
countries has been attributed to higher consumption of vitamin D rich fish, lighter skin
pigmentation, and sun seeking behavior among Northern European populations (83, 84).
In Denmark a little more than half (52.2%) of the population aged between 30 and
60 years old was reported to have 25(OH)D levels < 20 ng/mL while 13.8% of the
population had levels <10 ng/mL (85). In interpreting these data caution must be
exercised because vitamin D intake from supplements was not accounted for in their
analyses. The role of sedentary leisure time physical activity level was explored in this
survey and found to be a strong predictor of 25(OH)D levels less than 20 ng/mL.
However, interaction between leisure physical activity and age was not investigated
which still leaves an explanation gap as to why the prevalence of vitamin D deficiency
was greater in younger than older adults ( < 65 years) in the NHANES data or in data
from the UK’s National Diet and Nutrition Survey (NDNS) 1992 – 2000. In the NDNS,
the prevalence of 25(OH)D < 20 ng/mL peaked (75%) in the age group of 19 – 24 years
then declined before peaking again among those 85 years and above (86).
Adequate vitamin D status in postmenopausal women is critical because of poor
calcium metabolism associated with the postmenopausal period. Among 700 women
aged between 60 and 80 years old referred to one of the osteoporosis referral centers
across Italy, 27% of the subjects had 25(OH)D as low as less than 5 ng/mL while as
many as 76% had 25(OH)D levels less than 12 ng/mL (87). Notwithstanding the inherent
methodologic flaws associated with using data from clinical referral centers in this study,
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selection bias related to targeting of high risk patients, and the fact that 25(OH)D
measurements were taken at the end of winter season, this study still underscores the
severity of vitamin D deficiency in populations of postmenopausal women.
In a study of the prevalence of vitamin D insufficiency among 8532 communitydwelling postmenopausal women, mean age 74.2 years, with osteoporosis or osteopenia
across nine European countries, the prevalence of 25(OH)D levels less than 20 ng/mL
was 32.1% (88). The prevalence was even higher, 45%, when the analysis was restricted
to subjects under 65 years old. Even though the prevalence is relatively lower than what
was reported by Isaia et. al. (2003) in Italy, this disparity could be explained by some of
the factors associated with variable prevalence rates between European countries, as
discussed earlier. Most importantly, the 8,532 women included in the analysis already
had osteoporosis or osteopenia and hence may have already been taking vitamin D
supplements. Holick et. al. (2005) reported even lower prevalence (18%) of 25(OH)D
levels less than 20 ng/mL among North American postmenopausal women receiving
osteoporosis therapy (77).
In summary, the prevalence of adult vitamin D deficiency, defined as either
25(OH)D < 20 ng/mL or < 10 ng/mL, is high worldwide in darker skinned populations,
postmenopausal women, the elderly, and other nutritionally vulnerable populations.
Several other risk factors predispose individuals and populations to low 25(OH)D
concentrations. These factors and the prevention of deficiency D will be discussed in the
text below.
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1.3.4 Causes and Prevention of Adult Vitamin D Deficiency
Nutritional deficiency occurs when there is a disruption or malfunctioning in the
synthesis of a nutrient from its endogenous or exogenous source. Endogenous synthesis
of vitamin D from exposure to UVB radiation from the sun and diet are the major sources
of vitamin D for humans – the rest is derived from vitamin D supplements (59, 68, 89,
90).
Exposure to sunlight at wavelengths in the UVB region (290 – 315 nm) is altered
by several demographic, environmental and lifestyle factors. Lower latitude regions
definitely have higher UVB radiation intensity compared to higher latitude regions.
Indeed, ecological and within country (France) studies report relatively higher mean
serum 25(OH)D concentrations in populations from regions close to the equator (83, 91).
However, residence in lower latitudes don’t always guarantee adequate serum vitamin D
concentrations as demonstrated by multicenter studies in Europe where the prevalence of
25(OH)D levels less than 10 ng/mL was lower in populations residing in higher latitudes
(84, 85). In temperate regions such as Europe, skin synthesis of vitamin D is optimized
during the middle of the day (68). Hence the duration of outdoor activities, style of
dressing, sunscreen use, and air pollution are all modifiable risk factors for low cutaneous
synthesis of vitamin D (68, 86, 90). The non-modifiable risk factors are darker skin
pigmentation and older age (> 65 years). The prevalence of vitamin D deficiency in
darker skin populations is higher than in lighter skin populations. Even though the
prevalence of low vitamin D may peak in younger adults (19 – 24 years) in the US, the
prevalence rises after the age of 65 years for all racial groups (68, 79, 80, 86, 88, 90).
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Low vitamin D consumption from foods and supplements is often related to
socioeconomic, cultural, dietary lifestyles, and governmental nutritional policies (63, 79,
80, 82, 86, 92). For instance, it is mandatory in some countries, particularly developed
countries, to fortify certain foods like milk, fruit juices, and cereals. These countries are
also more likely to formulate public health programs for nutritionally vulnerable
populations like children, pregnant and lactating women, and the very elderly.
Populations that consume relatively higher quantities of oily fish are also more likely to
be at lower risk for vitamin D deficiency.
Several disease conditions or malfunctioning in organs involved with the
metabolism of vitamin D – liver and kidney – also increase the risk of vitamin D
insufficiency. Individuals with liver failure lose the ability to synthesize adequate
amounts of 25(OH)D (93, 94). Synthesis of 1,25(OH)2D occurs primarily in the kidney,
hence this function is lost in people with chronic kidney disease (93, 95). Decrease in the
bioavailability of vitamin D can also occur in the presence of malabsorption conditions
and obesity (96-98). In obese individuals, excess adipose fat tends to sequester vitamin D
in the body thereby reducing its availability for normal biological functioning (94, 99,
100).
1.3.5 Prevention of Adult Vitamin D Deficiency
Setting the recommended daily allowance (RDA) for vitamin D has been as
contentious as the definition of vitamin D deficiency in adults. This disagreement elicited
responses from two major position documents for guidelines on the RDA for vitamin D
from the Institute of Medicine and the Endocrine Society (61, 92). In 2010, the Institute
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of Medicine (IOM) updated a previous report and recommended RDA values based on
the IOM’s conclusions that serum concentrations of 25(OH)D above 20 ng/mL were
required for optimum bone health in diverse populations (74). The IOM recommended
RDAs for individuals between 1 and 70 years of age of 600 IU/day and 800 IU/day for
those above 70 years old. While the Endocrine Society Clinical Practice Guideline agrees
with the recommendations put forth by the IOM, they made revisions based on, in
addition to bone health, muscle functioning and 25(OH)D levels above 30 ng/mL. The
Endocrine Society proposed minimum supplementation of at least 1,000 IU/day and
1,500 – 2,000 IU/day to achieve minimum serum 25(OH)D > 30 ng/mL for age groups 1
– 18 years, and 19 + years respectively. The Endocrine Society guidelines are for “at
risk” clinical populations, however, as opposed to the IOM’s public health
recommendations for generally healthy populations. Bischoff-Ferrari et. al. (2006)
recommended consumption of 1000 IU/d vitamin D to achieve serum concentrations of
30 ng/mL in at least 50% of the adult population (101). These reports also recommended
vitamin D daily intakes for the prevention of some muscoloskeletal disorders and
colorectal cancer. Lastly, the IOM also proposed tolerable upper level intakes of 4,000
IU/day, 3,000 IU/day and 2,500 IU/day for 9+, 4 – 8, and 1 – 3 year groups respectively
(74).
1.3.6 Consequences of Low Vitamin D Status on Non-musculoskeletal Conditions
Among Adults
The relationship between low vitamin D status and several non-musculoskeletal
diseases in humans has also been controversial. Mortality data reflect the overall health
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status of a population; hence, the association between vitamin D status and mortality has
been extensively studied (102-106).
1.3.7 Vitamin D and Mortality
Observational studies
A meta-analysis of 13 observational studies reported a 42% increase in risk of allcause mortality (RR = 1.42, 95%CI: 1.23-1.63) associated with the lowest category of
serum 25(OH)D compared to the highest (or referent category) (102). Even though the
authors complied with most of PRISMA’s (Preferred Reporting Items for Systematic
reviews and Meta-analysis) guidelines, some methodological issues still need to be
addressed. First, most of the 13 studies were poor in quality because they were not
originally designed to test the association between serum 25(OH)D levels and mortality.
For example, one of the studies that contributed most of the sample (13%) had a very
short follow-up period of just 1.3 years (103). Reverse causality could not be ruled out in
such a short study. This study also failed to adjust for physical activity, BMI, and
smoking status which could have confounded the reported effect estimate of HR = 1.77
(95% CI: 1.49 – 2.10). The largest study by Melamed et. al. (2008) which contributed
13.8% of the analytical sample had long follow-up periods between 6 – 12 years and
adjusted for pertinent confounders (104). A significant risk (HR) of 1.28 (95% CI: 1.28 –
1.48) was still observed for all-cause mortality, albeit relatively weaker. Lastly, there
were inconsistencies in the definition of vitamin D deficiency based on serum 25(OH)D
levels between the 13 studies reviewed. Specifically, most of the studies used cut-off
values below the recommended 20 ng/mL (50 nmol/mL) levels for vitamin D
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insufficiency. Accordingly, the author posited the mortality risk observed in their metaanalysis was underestimated (102).
Other large observational studies in adult populations have also reported increased
risk of all-cause mortality with low serum 25(OH)D levels (105, 106). Among a
prospective cohort of 3,258 subjects with mean age 62±10 years referred for coronary
angiography at a single center in Germany, the risk of mortality associated with the lower
quartile of 25(OH)D was about 67% higher compared to those in the upper quartile. For
the two lower quartiles with median 25(OH)D concentrations of 7.6 ng/mL and 13.3
ng/mL respectively, the associated HR were 2.08 (95% CI: 1.60 – 2.70) and 1.53 (95%
CI: 1.17 – 2.01) respectively. The cardiovascular mortality risk associated with these
same lower quartiles of serum 25(OH)D levels were 2.22 (95%CI: 1.57 – 3.13) and 1.82
(95%CI: 1.29 – 2.58) respectively (105). However, caution has to be exercised when
interpreting the CVD mortality risk in this population because of the high all-cause
mortality rate (22.6% for 7.7 years median follow up) in this population. The high allcause mortality rate is indicative of the relatively poor health status of this population
which could have been a residual confounder for the 25(OH)D-CVD mortality
association.
In the general USA adult population, 2001 – 2004 NHANES, the risk of all-cause
mortality associated with 25(O)D levels was not strong. In multivariable analysis, the risk
(HR) of all-cause mortality among those with 25(OH)D < 20 ng/mL compared with those
with ≥ 30 ng/mL was 1.28 (95% CI: 0.86 – 1.90) (106). A drawback to this analysis lies
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with the relatively short median follow-up time of 3.8 years for mortality in a relatively
young and healthy population of 7,531.
In appraising existing evidence, observational studies support an inverse
association between serum 25(OH)D concentrations and all-cause mortality. The next
scientifically logical step is to investigate the effect of vitamin D supplementation and
mortality in randomized controlled trials to rule out the possibility of bias and reverse
causality. Several randomized trials of vitamin D have been conducted among primary
prevention populations to test its effect on fractures in older adults. Data from such
studies have also been analyzed to test the effect of vitamin D supplementation (alone or
combined with calcium) on all cause mortality.
Randomized controlled trials (RCTs)
Two different meta-analyses of vitamin D RCTs concluded that vitamin D
supplementation was protective against all-cause mortality. In the first published metaanalysis by Autier and Gandini (2006), 18 RCTs of vitamin D (D2 or D3) published
before 2007 involved a total sample of 57, 311 with 4,777 deaths and a mean 5.7 years
period. A 7% reduction in all-cause mortality risk (RR = 0.93, 95%CI: 0.87 – 0.99) was
achieved with supplementation of a trial size-adjusted mean daily vitamin D dose of 528
IU (107). A few observations should be considered when interpreting the results from this
meta-analysis. First, none of the 18 trials in the meta-analysis pre-specified mortality as
their primary outcome. Second, while most of these trials were conducted in older (≥ 64
yrs) populations who are at increased risk of fractures, data from the WHI vitamin D and
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calcium trial (N = 36,282), which contributed half of the analysis population, included
relatively younger females (108).
Findings of the meta-analysis by Autier and Gandini (2006) have been confirmed
by the most extensive meta-analysis on vitamin D supplementation and all-cause
mortality (7). Bjelakovic et. al. (2011) conducted exhaustive searches of all major
databases as well as consultation with experts and pharmaceutical companies for
additional data. Fifty published randomized trials of supplemental vitamin D (D 3 or D2),
or its active forms (calcitriol or alfacalcidol) were included in the analysis – 32 of these
trials combined supplemental vitamin D with calcium. The majority (44/50) of these
trials were primary prevention trials with a total of 93,585 subjects that included healthy
volunteers, postmenopausal women, and the elderly. The relative risk (RR) of all-cause
mortality associated with total vitamin D supplementation with a median daily intake of
800 IU, 1,000 IU, 1 µg, and 0.5 µg of D3, D2, alfacalcidol, and calcitriol respectively and
calcium (among 32 trials) was 0.97 (95% CI: 0.94 – 1.00). When stratified on the quality
of trials reviewed, the risk estimate was slightly reduced and remained significant, 0.95
(95% CI: 0.91 – 0.99), among 26 low bias studies, but was slightly higher and not
significant among 24 high bias studies. Compared to the other vitamin D analogues that
were used in the trials, D3 was the only one observed to be significantly associated with
reduced risk of all-cause mortality, 0.94 (95% CI:0.91 – 0.98). The authors also
emphasized the importance of knowing the baseline vitamin D status of trial participants
by showing that the intervention was only effective among participants with vitamin D
insufficiency at baseline. The analysis also reported that vitamin D significantly reduced
the risk of death among only participants who received dosages less than 800 IU/day.
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This supports a proposition by Shapses and Manson, IOM committee members, that
“more is not necessarily better” (109).
Only a small reduction, 3%, in all-cause mortality was achieved through
supplementation, however, this study had sufficient statistical power to detect such a
small effect estimate. The follow-up periods for most of these 50 trials were relatively
short – 39 of the 50 trials had follow-up years of 3 years or less. Other important lessons
were learned from this large meta-analysis. While vitamin D significantly decreased the
risk (RR = 0.95, 95% CI: 0.91 – 0.99) of mortality for participants with 25(OH)D ≤ 20
ng/mL at baseline, there was no benefit for those already with 25(OH)D ≥ 20 ng/mL
vitamin D status at baseline.
A drawback to the meta-analysis studies of both observational and randomized
trials is that some of the studies did not have enough long follow-up periods to fully
assess the effect of the supplementation. The short durations of follow-up also makes it
difficult to rule out mortality due to preexisting conditions. However this temporality
effect would have been similar in both intervention and control groups for RCTs. In
conclusion, it appears vitamin D supplementation significantly reduced the risk of allcause mortality by modest magnitude. Furthermore, low serum 25(OH)D levels also
predicted higher risk of all-cause mortality.
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CHAPTER 2

EVIDENCE FOR ASSOCIATION BETWEEN VITAMIN D DEFICIENCY AND
HEART FAILURE
2.1 Proposed Mechanisms by Which Vitamin D may Reduce CVD Risk
The ubiquity of vitamin D receptors in human tissues including cardiac muscle
has stimulated research on the pathophysiological role of vitamin D in CVD and HF
pathogenesis. Several plausible mechanisms have been proposed. These mechanisms
suggest vitamin D may affect cardiometabolic function through intermediate pathways or
systems, Figure 2 (110). Pathophysiological evidence in human studies, however, is
limited, and most data are derived from animal studies.
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Figure 2. Potential mechanisms for cardiovascular effects of vitamin D deficiency
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The renin-angiotensin-aldosterone system (RAAS) plays a major role in HF
pathogenesis by regulating blood pressure, cardiac contractility, electrolyte homeostasis,
and eccentric hypertrophy of the myocardium (111, 112). It has been demonstrated that
mice without the vitamin D-receptor (VDR) developed high blood pressure, cardiac
enlargement and experience increased activation of the RAAS (113). The activation of
RAAS by low vitamin D status has recently been noted in human studies (114, 115).
Among healthy normotensive subjects, Forman et. al. (2010), observed vitamin D
deficiency (25[OH]D < 15 ng/mL) to be associated with elevated levels of angiotensin II
(ang II) as well as blunted plasma renin flow (114). In another study, by Tomaschitz et.
al. (2010). Both 25(OH)D and 1,25(OH)2D levels were identified as independent
predictors of plasma renin concentrations (PRC) and Angiotensin II levels among
patients referred for coronary angiography; decreasing levels of both vitamin D markers
were correlated with higher PRC and Ang II levels (115). Lower 25(OH)D
concentrations had already been previously shown to be associated with increased risk of
stroke and heart failure mortality in this population (105, 116, 117). This suggests a
strong plausible role of vitamin D in regulating the RAAS in HF pathogenesis.
Hyperparathyroidism has also been postulated as an intermediate process in
vitamin D-heart failure pathophysiology. Evidence for this derives from studies in
patients with end-stage renal disease (ESRD) (14-17). ESRD patients lose the ability to
convert 25(OH)D to the metabolic form of 1,25(OH)D2, leading to secondary
hyperparathyroidism and elevation of circulating parathyroid hormone (PTH) levels (10,
15-17). Chronic exposure to PTH has been reported to be associated with abnormal
myocardial structure and functioning as well as elevated blood pressure and accelerated
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atherosclerosis. Excess PTH may also lead to cardiomyocyte hypertrophy which is an
important risk factor for HF and especially among hemodialysis patients (13, 15, 118).
A pathophysiologic model of a direct vitamin D effect on cardiac function has not
been extensively studied in humans. However, data from animal models suggest that
vitamin D may regulate cardiac functions via interaction with vitamin D receptors (VDR)
in cardiac myocytes (10, 119). Vitamin D (1,25[OH]2D) regulates intracellular calcium
homeostasis and calcium ion uptake in ventricular cardiac muscle cells through a
receptor-mediated mechanism to modify cardiac contractility (120). To demonstrate this,
physiological functioning markers in VDR-knockout mice and wild type mice were
compared through histological staining of their cardiac tissues after 12 months of life.
Poor physiological cardiac functioning markers, cardiac hypertrophy, cardiac fibrosis,
collagen deposition, were all observed in the VDR-knockout mice but not in the wild
type mice (11, 12).
Evidence from both human and animal studies suggests vitamin D regulates
cardiac functioning via direct and indirect routes. Vitamin D can directly affect cardiac
functioning through interaction with cardiomyocyte VDR or indirectly by modifying the
major risk factors associated with HF.
2.2 Association between Low Vitamin D Exposure and Heart Failure
However, only two published observational studies have investigated a direct
relationship between vitamin D deficiency and HF incidence among a cohort free of heart
failure at baseline (103, 116). Additional data on this topic are derived from clinical trials
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of vitamin D supplements among prevalent HF cases (121-123). These studies are
discussed.
RCT data among HF patients
There is an absence of RCTs of the primary prevention role of vitamin D in HF.
However, secondary prevention trials of HF outcomes through vitamin D
supplementation are reviewed; secondary prevention data are essential in understanding
the pathophysiological role of an intervention in the pathogenesis of a disease. In
Germany, 123 middle-aged (50 – 63 years) HF patients were randomized to treatment
with daily doses of 2000 IU cholecalciferol and 500 mg Ca or to 500 mg calcium only
(control) for nine months (121). Statistically significant reductions in mean parathyroid
hormone levels and elevation in Interleukin-10 levels were observed in the treatment
group but not in control group. Additionally, tumor necrosis factor-α levels remained
unchanged in the treatment group but increased in the control group suggesting that
vitamin D suppresses this marker of inflammation. However, vitamin D supplementation
had no observed effect on left ventricular ejection fraction or N-terminal fragment brain
natriuretic peptide (NT-proBNP) levels. This trial suggests vitamin D may be associated
with positive changes in the anti-inflamatory milieu of HF patients but may not improve
ejection fraction once disease is established.
Results of other studies have been inconsistent. Among 69 elderly HF patients
(mean age, 79 years), supplementation (with 100,000 IU of ergocalciferol) resulted in
significant reduction in NT-proBNP levels (secondary outcome) after 20 weeks, -52
pg/mL, p = 0.05, but did not improve physical functioning or quality of life (122).
Another study, among African Americans (n = 14), reported attenuation of
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hyperparathyroidism, oxidative stress, and improvement in ventricular function after a
fourteen week regimen of vitamin D and calcium supplementation (123).
Observational cohort studies
Results from observational studies also suggest an association between low
vitamin D status and HF. Very low 25(OH)D levels (≤15ng/mL) were associated with a
two-fold increase in HF incidence (HR=2.01, p < 0.0001) in a population of 23,793
middle-aged (≥ 50yrs) subjects derived from a database of electronic medical records
(103). A prospective study among 3,299 patients in Germany, free of HF and referred for
coronary angiography, reported inverse associations between 25(OH)D and 1,25(OH)2D
levels and NT-proBNP levels (R = 0.190; P < 0.001). Both vitamin D metabolites were
positively correlated with left ventricular function measured with contrast
ventriculography (P < 0.001 for both). Furthermore, persons with 25(OH)D levels within
the lowest quartile were at elevated risk of HF mortality, HR=2.64, 95%CI (1.47– 4.72),
compared to those in the highest quartile (116).
2.3 Association between low vitamin D exposure and major HF risk factors
There is a moderate but inconsistent body of evidence to support inverse
associations between vitamin D levels and major cardiovascular precursors of HF hypertension, diabetes, and cardiovascular diseases (especially myocardial infarction,
angina, and valvular heart disease) (19). The American College of Cardiology (ACC)
classifies individuals with hypertension, cardiovascular diseases, coronary heart
diseases/events, or diabetes but who have not yet developed structural abnormalities like
left ventricular dysfunction or hypertrophy or geometric chamber distortion as ‘Stage A’
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heart failure and those who demonstrate any of these structural abnormalities as ‘Stage
B’. While Stages A and B heart failure are not HF per se, these designations enable
healthcare providers to identify individuals at the greatest risk of HF for early
interventions (18). In the general female population between the ages of 40 – 89 years,
hypertension, diabetes, and CVDs are associated with population attributable risks (for
HF) of 59%, 12%, and 26%, respectively (19). Interestingly, these precursors of HF have
also been found to be inversely correlated with serum vitamin D levels (5-9). Hence,
these cardiovascular risk factors can potentially modify the vitamin D-HF relationship –
this supports the indirect effect of vitamin D on HF model. Hence, if vitamin D
supplementation can reduce the prevalence or improve the prognosis of these risk factors,
then HF risk may be curtailed. It is therefore important to evaluate the role of vitamin D,
with/without calcium, in both incident and prevalent cohorts of cardiovascular disease
risk factors.
A prevalent cohort has been described as a study population with risk factors for
the outcome of interest and/or the outcome of interest during a specific period of time. In
contrast, an incident cohort consists of a population free of both the risk factors and/or the
outcome at the inception of the cohort but who are at risk of developing the risk factors
and/or outcome during the study period (124). Prevalent and incident cohorts tend to
differ considerably on baseline and prognostic characteristics of the disease of interest
(124). To demonstrate this phenomenon, Buckley et. al. (2010) evaluated survival in both
prevalent (first acute myocardial infarction) and incident cohorts derived from primary
care and death certificate linked data. During a five year period, there were more deaths
(from all-cause [34%] and ischemeic heart disease, IHD [18.5%]) in the prevalent cohort
37

than in the incident cohort (all-cause [18%] and IHD [12.2%]). This is why it is important
to evaluate the effect of the intervention, calcium plus vitamin D, in the vitamin D and
calcium trial of the WHI study in both incident and prevalent cohorts. The associations
between vitamin D and known strong risk factors of HF are reviewed below.
2.3.1 Cardiovascular Diseases (CVD)
Evidence from RCTs
The association between vitamin D alone or combined with calcium and the risk of CVD
incidence is equivocal and based on sparse RCT data. Wang et. al. (2010) systematically
reviewed and conducted a meta-analysis of RCT data on vitamin D and calcium
supplementation and the risk of CVD events (5). On calculating a pooled RR for the
association between vitamin D alone and CVD incidence assessed as a secondary
outcome, only two studies met the inclusion criteria for the review - Trivedi et. al. (2003)
and Prince et. al. (2008) (5, 125, 126). The study by Trivedi et. al. (2003) contributed
90% of the analytical sample, supplemented 100,000 IU of oral vitamin D3 per every four
months (an average of ~833 IU/day) to a placebo matched group (1,019 men and 326
women) community-dwelling population of 65 years and above (total N = 2,686) in
Britain. The risk of composite CVD - ischemic heart disease (ICD-9; 410.0 - 414.0) and
cerebrovascular disease (ICD-9; 430.0 - 438.0) - assessed as a secondary outcome was
not significantly reduced (RR = 0.84, 95% CI: 0.65 – 1.10). It is also not clear if
administering oral vitamin D doses as high as 100,000 IU, above the IOM daily
threshold, every four months would have the same effect on CVD incidence as
supplementing daily doses within the recommended range. Given that Bjelakovic et. al.
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(2011) found daily vitamin D3 but not intermittent supplementation to be associated with
reduction of all-cause mortality, it is possible that daily supplementation is more
beneficial for CVD outcomes as well (7).
In the vitamin D combined with calcium pooled analysis, 99% of the analytical
sample came from the WHI trial while only 1% came from the other study, by Brazier et.
al. (2005) (5, 127, 128). The WHI intervention arm was supplemented with only 400
IU/day of vitamin D combined with 1000 mg/day of calcium. This amount was lower
than the revised recommended daily intake of 600 IU/day by the IOM for this age group,
which included diet plus supplements (92).
Vitamin D (alone or combined with calcium) supplementation had no effect on
myocardial infarction, stroke, or ischemic heart disease when investigated as individual
fatal or non-fatal CVD endpoints. When Trivedi et. al. (2003) stratified their analysis by
separate CVD endpoints, supplementation neither reduced the risk of ischemic heart
disease (ICD-9; 410.0 - 414.0) (RR = 0.94, 95% CI: 0.77 – 1.15) nor ischemic heart
disease mortality (RR = 0.84, 95% CI: 0.56 – 1.27) (125). In the WHI study,
calcium/vitamin D supplementation had no benefit on MI or stroke risk while in a
Another study based on the WHI data reported the intervention had no significant effect
on coronary heart disease (HR=1.01, 95%CI: 0.79 – 1.29) or cerebrovascular disease
mortality (HR=0.89, 95%CI: 0.62 – 1.29) (128, 129).
Observational cohort studies
The vitamin D – CVD association has been inconsistent in cohort studies. The
Framingham Offspring Study investigated CVD events as composite endpoint. Among
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1,739 men and women in this study (mean age 59 years), CVD incidence decreased in a
graded manner with increasing categories of 25(OH)D levels (p-trend = 0.01) but
appeared to plateau at levels around 24 ng/mL (117). Compared to 25(OH)D ≥ 15 ng/mL,
the risk of CVD incidence associated with levels < 15 ng/mL and < 10 ng/mL were 1.59
(95% CI:1.03 – 2.45) and 1.81 (95%CI:1.03 – 3.18) respectively (130). Total CVD
mortality risk on the other hand was inversely associated with 25(OH)D concentrations in
two (Dobnig et. al. [2008] and Kilkkinen et. al. [2009]) of the three studies selected for a
systematic review by Pittas et. al. (2010) (6). Dobnig et. al. (2008) reported the lower two
quartiles of 25(OH)D levels, 7.6 ng/mL and 13.3 ng/mL, to significantly predict elevated
risk of CVD mortality; 2.22 (95% CI: 1.57 – 3.13) and 1.82 (95% CI: 1.29 – 2.58)
respectively for the first (Q1) and second (Q2) lower quartiles (105). Reduced risk of total
CVD mortality (HR = 0.76, 95% CI: 0.60 – 0.95) was associated with the highest quintile
of 25(OH)D compared to the lowest in the Mini-Finland Health Survey by Kilkkinen et.
al. (2009). This study prospectively followed 6,219 participants aged 30 years and older
who were free of baseline CVD, for a period of (mean) 27 years in Finland (131). The
third study, based on NHANES III data, did not find a significant association between
25(OH)D levels and total CVD mortality (104). The systematic review by Pittas et. al.
(2010) is a good reported because it was conucted in accordance with factors from
recommended standardized forms of reporting, such as the STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology) and CONSORT (Consolidated
Standards of Reporting Trials) (132, 133). They did not meta-analyze the three studies
because of the heterogeneity in the definition of total CVD mortality between the studies.
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Myocardial infarction (MI) is the most consistent cardiovascular event
contributing to the incidence of HF (19). The association between MI and low vitamin D
status is inconclusive. Only one of the two studies included in the systematic review by
Pittas et. al. (2010) reported an association between MI and low vitamin D status (6). In
the Health Professionals Follow-up study, very low 25(OH)D serum concentrations (≤ 15
ng/mL) were associated with a two-fold increased risk of MI, HR = 2.09 (95% CI:1.24 –
3.54), compared to 25(OH)D ≥ 30 ng/mL (134). The other study failed to report the
specific 25(OH)D levels that were compared for association with MI – they only alluded
to using the lowest quartile as the referent category. The authors also failed to specify
which biomarker of vitamin D was used in their analysis as they measured both 25(OH)D
and 1,25(OH)2D concentrations (135).
2.3.2 Diabetes
The association between diabetes and vitamin D insufficiency is inconclusive.
Niether RCT nor cohort studies data provide sufficient evidence for a causal association
between vitamin D deficiency and type 2 diabetes. However, vitamin D deficiency might
still have a strong effect on prediabetes, which is a strong risk factor for HF.
Evidence from RCTs
Vitamin D supplementation had no significant effect on fasting plasma glucose
level among a population with normal glucose tolerance at baseline in a meta-analysis of
5 trials (6). However, one trial conducted a sensitivity analysis among a population with
impaired glucose tolerance at baseline (n = 222) and observed attenuation in increasing
fasting plasma glycemia through vitamin D (700 IU) and calcium (500 mg)
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supplementation (136). Recent data from the Randomized Placebo-Controlled Trial of
Vitamin D3 and/or Calcium (RECORD) trial among 5,292 participants aged 70 years and
above did not observe a significant effect of vitamin D (800 IU) supplementation alone or
with 1000 mg calcium (137). Vitamin D and calcium supplementation did not achieve a
significant reduction of the risk of type 2 diabetes, OR = 0.68 (95% CI:0.40 – 1.16)
among participants who complied with the treatment protocol after the second year of the
study, (137).
Prospective cohort studies
Only a few large prospective cohort studies have evaluated the association
between vitamin D status and type 2 diabetes. Of four studies that met the inclusion
criteria for a systematic analysis by Pittas et. al. (2010), only the Women’s Health Study
reported a significant association between vitamin D deficiency and the risk of type 2
diabetes (6). The Women’s Health Study defined vitamin D deficiency based on selfreported total vitamin D intake instead of the more sensitive biomarker, 25(OH)D, which
limits their findings (138). Another of the four reviewed studies which also poorly
assessed vitamin D deficiency by this total vitamin D intake method did not find
significant association between low vitamin D intake and risk of type 2 diabetes, HR =
0.87 (95% CI:0.69 – 1.09) (139). Data from a large medical records database (n = 41,504)
demonstrated that very low vitamin D status (25[OH]D ≤ 15 ng/mL) was associated with
increased incidence of diabetes mellitus compared to normal vitamin D status (25[OH]D
> 30 ng/mL) (103).
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The lack of observed strong associations between vitamin D and risk of type 2 diabetes
could be partly explained by study design issues. First, all of the studies reviewed here
ascertained diabetes cases through self-reports. While some reported cases were
validated, none of the studies screened the study population for diabetes or re-adjudicated
these cases to minimize misclassification bias. Second, most of the RCTs had small
samples and short duration of follow-up. The observational prospective cohort studies
also introduced misclassification errors into the ascertainment of vitamin D status by
using total vitamin D intake rather than 25(OH)D levels . Lastly, in addition to the
misclassification issue, it is possible that some participants were asymptomatic but were
pre-diabetic. To buttress this point, a recent publication of the NHANES III data reported
an association between low serum 25(OH)D levels and risk of pre-diabetes, OR = 1.47
(95% CI:1.16 – 1.85). The authors of this study defined pre-diabetes as “a 2-h glucose
concentration of 140–199 mg/dL, or a fasting glucose concentration of 110–125 mg/dL,
or an A1C value of 5.7–6.4%” among a sample of adults aged 20 years and over who
were free of diabetes and CVD (140).
2.3.3 Hypertension
One of the strongest biologically plausible benefits of vitamin D is its role in the
up- regulation of RAAS. It is hypothesized that vitamin D regulates blood pressure via
the RAAS. This hypothesis, however, has been investigated in both observational and
RCTs with equivocal conclusions.
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Evidence from RCTs
The findings regarding the effect of vitamin D alone or combined with calcium on
blood pressure has been inconsistent. The authors of the AHRQ systematic review of
health outcomes associated with vitamin D and calcium did not meta-analyze selected
trials because of the heterogeneity in study populations and follow-up periods (8).
However, a recent meta-analysis of 10 trials, Pittas et. al. (2010), reported no significant
reduction in either systolic nor diastolic blood pressures as a result of vitamin D
supplementation (6). The conclusion of this analysis warrants caution due to several
factors. First, based on their own assessment of the quality of these 10 trials, the authors
judged only 3 to be of “good quality”. Nevertheless, they pooled effect estimates from all
10 trials. Second, 9 of the 10 trials had very short follow-up periods, 5 – 52 weeks. The
notable exception is the WHI study with 7 years follow-up. WHI contributed about
97.6% (36,282) of the analytical sample for the meta-analysis (141). The WHI trial did
not find significant effect of combined vitamin D and calcium supplementation on either
systolic or diastolic blood pressure. Inherent study design issues such as the low vitamin
D dosage could have played prominent role in the outcome. Lastly, there was significant
heterogeneity between the studies, I2 = 69%, which raises concerns about the validity of
conducting the meta-analysis.
Observational cohort studies
Pittas et. al. (2010) meta-analyzed 3 studies from two cohorts and reported a 76%
increase in risk of hypertension (RR=1.76, 95%CI: 1.27 – 2.44) associated with the
lowest level of 25(OH)D (< 14.8 to 20.4 ng/dL) compared to the highest level (>30 to
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32.4 ng/dL) after 7 to 8 years of follow-up (6, 142, 143). However, among 1,206 adults
(≥ 65years) in the Netherlands, low vitamin D level (25[OH]D < 25nmol/L) was not
associated with hypertension (OR = 0.89, 95% CI: 0.47 – 1.69) (144). The prevalence of
vitamin D insufficiency, (25[OH]D < 20 ng/mL), 10.5%, was relatively low in this
elderly population, however. This could have been partly due to vitamin D supplement
intake, which the study did not assess or adjust for in their model.
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CHAPTER 3
METHODOLOGY
3.1 Objectives
3.1.1 Main Objective
The main objective of this study is to determine if supplementation with vitamin
D plus calcium reduced the incidence of hospitalization for heart failure (HF) among
postmenopausal women. Heart failure caries enormous healthcare cost, mortality, and
functional limitation yet there are inadequate preventive measures against HF at the
population level. The data reviewed above support the hypothesis that supplementation
with vitamin D among primary prevention cohorts might be protective against HF
incidence. However, there are no known published randomized trials that have
investigated such intervention for the prevention of HF. This study therefore seeks to fill
that knowledge gap by analyzing data from the vitamin D and calcium trial of the
Women’s Health Initiative (WHI) study. The WHI is an ongoing long-term health study
of postmenopausal women focused on preventing chronic diseases including heart
failure. The study was designed in two parts consisting of three clinical trials and an
observational study. The vitamin D and calcium (CaD) trial is one of the three clinical
trials nested within WHI, and was primarily designed to test the effect of vitamin D and
calcium intervention for the prevention of osteoporotic fractures and colorectal cancer.
However, heart diseases, including hospitalized heart failure, were assessed as secondary
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outcomes. This national population-based study is ideal for investigating the main
objective of this study.
3.1.2 Specific Aims
Specifically, the following aims will be evaluated to assess the impact of vitamin
D plus calcium supplementation on the incidence of hospitalization for HF.
i. To evaluate whether supplementation with vitamin D plus calcium is modified
by baseline risk status of heart failure. It is hypothesized that vitamin D may
protect against HF indirectly via minimizing the incidence and/or progression of
major HF risk factors.
ii. To assess whether self-reported total vitamin D and calcium intake at baseline
modified the association between the intervention and HF incidence. Participants
who reported adequate vitamin D intake may not benefit from this intervention
because of their optimal vitamin D status as previously observed (7).
By accomplishing the above objectives, this study will help explain the
pathophysiological role of vitamin D in heart failure pathogenesis. Additionally, results
of this study, if they demonstrate benefit, will be useful for design and implementation of
public health intervention against HF through vitamin D supplementation. Clinically, the
study may also help to inform clinical decision making about the utility of screening high
risk HF individuals for vitamin D deficiency.
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3.2 Hypotheses
Vitamin D plus calcium supplementation is associated with a lower risk of heart
failure. Populations that may be at relatively higher predisposition for developing heart
failure, owing to the presence of preexisting cardiovascular risk factors of heart failure
(stages A or B heart failure), will benefit more from this intervention compared to
populations without any preexisting baseline cardiovascular risk factors of heart failure.
Primary Hypothesis 1
Research hypothesis (H1): Vitamin D (400 IU/day) plus calcium (1000 mg/day)
supplementation was associated with lower risk of heart failure during an average of 7.13
(SD, 1.33) years of follow-up.
Null hypothesis (H0): Vitamin D (400 IU/day) plus calcium (1000 mg/day) was not
associated with risk of heart failure after randomization to vitamin D and calcium.
Primary Hypothesis 2
Preexisting baseline cardiovascular risk factors of heart failure modifies the association
between the intervention and heart failure incidence. While the intervention is associated
with lower risk of heart failure in both populations stratified by preexisting baseline
cardiovascular risk factors of heart failure, the effect estimate for this association is
higher in populations with these risk factors.
Research hypothesis (H2a): Calcium (1000 mg/day) plus vitamin D (400 IU/day)
supplementation was associated with lower risk of heart failure in populations
with preexisting baseline cardiovascular risk factors of heart failure during an
average of 7.13 (SD, 1.33) years of follow-up.
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Null hypothesis (H0): The intervention is not associated with risk of heart failure
after randomization to vitamin D and calcium in this population.
Research hypothesis (H2b): Calcium (1000 mg/day) plus vitamin D (400 IU/day)
supplementation was associated with lower risk of heart failure in populations
without preexisting baseline cardiovascular risk factors of heart failure during an
average of 7.13 (SD, 1.33) years of follow-up.
Null hypothesis (H0): The intervention is not associated with risk of heart failure
after randomization to vitamin D and calcium in this population.
Secondary Hypothesis
Participants were allowed to continue the consumption of personal calcium (≤
1,200 mg/day) and vitamin D (≤ 600 IU/day) supplements while enrolled in this trial due
to ethical reasons. Hence, total (from diet and supplements) vitamin D and calcium
intakes may have modified the associations between the intervention and heart failure
incidence.
Research hypothesis (H3a): Baseline self-reported total vitamin D intake modified
the association between the intervention and risk heart failure incidence.
Null hypothesis (H0): Baseline self-reported total vitamin D intake did not modify
the association between the intervention and heart failure incidence after
randomization to vitamin D and calcium.
Research hypothesis (H3b): Baseline self-reported total calcium intake modified
the association between the intervention and risk heart failure incidence.
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Null hypothesis (H0): Baseline self-reported total calcium intake did not modify
the association between the intervention and heart failure incidence after
randomization to vitamin D and calcium.
3.3 Overview of the WHI study
In 1991, the National Institute of Health established the Women’s Health Initiative
(WHI) study. The initiation of this study was aided by strong public interest in women’s
health backed by political will and interests from the scientific community to identify
preventive strategies for colorectal and breast cancers, cardiovascular diseases, and
osteoporotic fractures (145). The WHI study with 161,000 participants and a financial
budget of $628 million for fifteen-year period makes it the largest of its kind (146).
A Clinical Coordinating Center (CCC) was established to develop drafts of the study
protocol and collect, manage and analyze data. Additionally, forty Clinical Centers (CC)
were established across the United States of America to recruit and enroll participants
into the WHI study. WHI began enrolling participants in the Fall of 1993. This large
study of postmenopausal women consisted of three clinical trials (CT) and one
observational study. Initially, women recruited into the study had the choice to enroll in
either the Hormone Therapy (HT) or Dietary Modification (DM) trials or both. After a
year of two, participants of these two trials were invited to join the Calcium plus Vitamin
D (CaD) trial. Women who did not join any of the three trials were invited to be part of
the observational study. These studies are described later in this chapter. Participants
were followed through to 2005 to close out the trials and the observational study.
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However, the WHI study was extended two more times, 2005 – 2010 and 2010 – 2015 to
continue collecting follow-up data on consenting participants.
Details of the WHI study design and implementation have already been published
(146, 147). More than 161,000 women (50 – 79 years old) were recruited for the study
making it the largest study among postmenopausal women. Postmenopausal period was
defined as no menstrual period for at least 6 months if ≥ 55 years or absence of menstrual
period for a period of at least 12 months if between 50 and 54 years old. Three clinical
trials (Dietary Modification, Hormone Therapy, and Vitamin D and calcium) and an
observational study were designed to assess prevention therapies for diseases and the
overall health and well-being of postmenopausal women (146, 147). A total of 68,132
postmenopausal women in the age groups of 50 – 54 years (10%), 55 – 59 years (20%),
60 – 69 years (45%), and 70 – 79 years (25%) were recruited at 40 clinical sites over the
U.S. and randomized to each of the three clinical trials (CT). There was considerable
overlap of participants between the three CTs as depicted in Figure 3 (147).
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Figure 3. Overlap of participants enrolled in the three clinical trials (HT, DM, and CaD)
of the Women’s Health Initiative (WHI) study.

Dietary Modification (DM) Trial
The dietary modification (DM) trial was designed to assess the impact of a low fat
dietary pattern on colorectal and breast cancers as major primary outcomes and CVDs as
secondary outcomes. Of the 48,435 individuals recruited into the DM trial, 40% were
randomized to a sustained low fat dietary eating pattern while 60% were randomized to
the control group to maintain a self-selected dietary behavior. The intervention arm was
designed to achieve a 20% reduction in total dietary fat and 7% reduction of saturated fat
intake per corresponding total caloric intake. The secondary objectives of the intervention
were to increase daily vegetable and fruits intake to six and grain products intake to five.
Further details of the DM trial are published elsewhere (146, 148).
52

Hormone Therapy (HT) Trial
The Hormone Therapy (HT) trial design, implementation, and safety concerns
about the intervention have been published (149-151). The HT recruited 27,500
postmenopausal women for a double-blind 1:1 randomized study on the effects of two
forms of estrogen on coronary heart disease (CHD). The form of the estrogen was
dependent on the hysterectomy status of participants during randomization. Hip and other
bone fractures were assessed as secondary outcomes while breast cancer was investigated
as an adverse outcome. At randomization, post-hysterectomy women (n=10,739) were
randomized to unopposed estrogen therapy of conjugated equine estrogen (E alone) 0.625
mg/day or placebo while women with an intact uterus (n=16,068) were randomized to the
same preparation of estrogen plus continuous 2.5 mg/day of medroxyprogesterone acetate
(E + P) daily or placebo. In the year 2002, the E + P trial was stopped prematurely by the
WHI Data and Safety Monitoring Board (DSMB) owing to accumulated evidence that E
+ P was associated with increased risk of breast cancer and CVD. It was also observed
that the overall risk-to-benefit ratio of the intervention was elevated during this period.
Subsequently, in 2004 the E alone trial was also stopped by the DSMB after accumulated
evidence of increased risk of stroke and no benefit for CHD (152).
3.4 The Calcium plus Vitamin D (CaD) Trial
The study design and methodology of the CaD study has already been published
(147, 153). Cardiovascular diseases, colorectal and breast cancer, and osteoporotic
fractures were identified as the most important health outcomes in older women. The
vitamin D and calcium (CaD) trial was initiated as the last of the three trials to primarily
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evaluate the impact of vitamin D and calcium supplementation on hip fractures and
colorectal cancer. CVDs, including heart failure, were assessed as secondary outcomes.
The primary eligibility for enrollment in this trial was prior enrollment in at least one of
the other trials, DM and/or HT. Participants who reported use of personal vitamin D ≤
600 IU/day and/or calcium ≤ 1,000 mg/day supplements were allowed to continue taking
them even after enrolling in the CaD trial. The personal vitamin D supplement
consumption was raised to an upper limit of 1,000 IU/day after the IOM published new
recommendations on vitamin D intake in 1999 (154). A total of 68,132 (27,347 HT and
48,835) participants were screened for eligibility and recruitment into the CaD trial.
Details of participant selection for the CaD trial and the present analyses are reported in a
schematic flow diagram (Figure 4) based on CONSORT’s guidelines (155).
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Figure 4. Participant recruitment and selection for the CaD trial and analysis
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3.4.1 Eligibility Criteria
In addition to the exclusion criteria reported by Hays et al. (2003) for the three CTs
(Table 1), participants were excluded from the CaD trial for safety reasons if they
reported history of renal calculi, hypercalcemia, or use of corticosteroids or calcitriol
(156). To reduce the effect of competing risks, individuals were excluded if they had any
medical conditions associated with less than a 3 year survival. Additionally, with
intention to continue consuming vitamin D supplements at dosages ≥ 600 IU/day and
calcium supplements at dosages ≥ 1,000 mg/day were excluded. Based on these
restrictions, 31,850 women were ineligible to participate in the CaD trial.
Women were eligible for recruitment if they were between 50 to 79 years of age and
postmenopausal. In addition to providing informed consent, other eligibility criteria were
based on adherence (willingness to take study pills and symptom management) and
retention (intention to reside in current area for at least 3 years and attend clinic sessions).
After meeting these requirements, 36,282 participants were asked to sign informed
consent forms to indicate their willingness to participate in the CaD trial.
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Table 1
WHI inclusion and exclusion criteria
Component
Clinical trial and
observational study

Inclusion
50–79 years of age
Postmenopausal
If age <55, no menstrual
period for at least 6 months
If age 50–54, no menstrual
period for at least 12 months
Ability and willingness to
provide written informed
consent (component specific)
Intention to reside in area
for at least 3 years

Clinical trial and
observational study

Exclusion

Competing risk:
Any medical condition with predicted survival
of < 3 years
Adherence or retention reasons:
Alcohol or drug dependency
Mental illness, including severe depression
Dementia
Active participation in other randomized
intervention trial
Competing risk:
Any invasive cancer in previous 10 years
Breast cancer at any time
Mammogram or CBE findings suspicious of
breast cancer
MI in previous 6 months
Stroke or TIA in past 6 months
Chronic hepatitis or severe cirrhosis
Safety reasons:
Severe hypertension (systolic BP > 200 mm
Hg or diastolic BP > 105 mm Hg)
Severely underweight (BMI _18 kg/m2)
Hematocrit < 32%
Platelets < 75,000 cells/ml
Current use of oral daily corticosteroids
Adherence or retention reasons:
Unwilling to participate in baseline or followup examination components
Adherence or retention reasons:
Special dietary requirements incompatible
with the intervention (e.g., celiac sprue)
On a diabetic or low salt diet
Gastrointestinal conditions contraindicating a
high fiber diet
Type 1 diabetes
Colorectal cancer at any time
Routinely eat ≥10 meals per week prepared
out of the home
Unable to keep a 4-day food record

Clinical trial

Dietary modification
(DM)
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FFQ percent calories from fat <32%
FFQ energy intakes <600 or >5000 kcal
Previous bilateral prophylactic mastectomy
Safety reasons:
Endometrial cancer at any time
Endometrial hyperplasia
Malignant melanoma at any time
History of pulmonary embolism or deep vein
thrombosis
Previous osteoporosis-related fracture being
treated with hormones
History of bleeding disorder requiring
transfusion
History of hypertriglyceridemia
Currently on anticoagulants
Currently on tamoxifen
Abnormalities in baseline pap smear, pelvic
exam, or pelvic ultrasound
Adherence or retention reasons:
Severe menopausal symptoms that would
make placebo treatment intolerable
Inadequate adherence to placebo run-in
Unable or unwilling to discontinue use of PHT
or testosterone
Refusal to have baseline endometrial
aspiration
Safety reasons:
History of renal calculi or hypercalcemia
Current use of oral corticosteroids or calcitriol
Intention to continue taking ≥600 IUs of
vitamin D per day

Postmenopausal
hormone therapy
(PHT)

Vitamin D and calcium
(caD)

Abbreviations: BMI, body mass index; BP, blood pressure; CBE, clinical breast exam; FFQ, food frequency
questionnaire; PHT, postmenopausal hormone therapy; TIA, transient ischemic attack.
Reference: Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann
Epidemiol 2003;13(9 Suppl):S18

3.4.2 Characteristics of the CaD Trial Population
Of the total CaD trial population, only 13.8% (n = 5,017) of them were enrolled in both
DM and HT trials and more than half were enrolled in DM alone (Figure 1). The mean
age of the population was 62 ± 6.9 years with 45.5% between 60 – 69 years old. While
efforts were made to increase minority populations participation, only 16.9% of enrolled
participants belonged to one of the four minority or unknown race/ethnic groups (Table
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2) (156). African Americans made up more than half (54.1%) of the minority and
unknown racial populations.
Table 2
Summary of demographic characteristics of participants recruited into the CaD trial
before randomization.
Baseline characteristics

N or Mean (± SD)

%

DM

20,193

55.7

HT

11,072

30.5

Both

5,017

13.8

WHI clinical trial

Age (years)
Mean

62.4 (± 6.9 years)

50 – 59

13,422

37.0

60 – 69

16,520

45.5

70 – 79

6,340

17.5

Non-Hispanic white

30,153

83.1

Black

3,317

9.1

Hispanic

1,507

4.2

Asian/Pacific Islander

722

2.0

American Indian

149

0.4

Unknown

434

1.2

Race/Ethnicity
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3.4.2 The CaD Trial Randomization
The 36,282 postmenopausal women who met the inclusion criteria and agreed to
participate in the CaD trial were randomized in a 1:1 ratio double-blind fashion to receive
either the intervention or placebo. The intervention group was supplemented with tablets
composed of calcium carbonate (containing 500 mg of elemental calcium) and 200 IU
vitamin D3. These pills were initially in chewable forms but after October 1997
swallowable forms were made available to enhance participants’ tolerance to study
medication (153). Participants were instructed to take these tablets twice daily with meals
to maximize the absorption of vitamin D and calcium. Hence, the intervention group
received a total dosage of 1,000 mg calcium and 400 IU vitamin D per day (147, 153).
This dose, according to the IOM, was sufficient to meet the recommended daily
allowance (RDA) of both vitamin D and calcium in postmenopausal women. Participants
randomized to the placebo group were provided ‘inactive’ tablets which looked exactly
like the ‘active’ tablets and instructed to take these tablets in the same format as those in
the intervention group to preserve the blinding of the randomization to both study staff
and participants (153).
3.4.3 Adherence to Intervention
WHI pre-defined adherence in the WHI manual as taking CaD study pills that
amount to at least 80% of the appropriate amount (157). During annual and semi-annual
visits, study staff weighed pills returned from participants before new ones were
dispensed. Adherence was then estimated by dividing the difference between the weights
of the original and returned pills by the original weight. These routine monitoring of
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adherence to study medication allowed WHI to assist and encourage participants with
low adherence rate to improve their adherence. One of the programs implemented by
WHI to improve adherence was the “Intensive Adherence Program” through which study
staff contacted low adherence participants outside the routine study visits. Details of this
program and issues on adherence are found in the WHI study manual (157). After eight
years of follow up, 59% of the population was observed to be taking at least 80% of their
medication, Figure 5 (108).

Figure 5. Adherence rate to study protocol in the vitamin D plus calcium trial of the WHI
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3.4.4 Data Collection Methods
A total of 40 clinical centers were established throughout the United States of
America to recruit postmenopausal women into any of the three CTs or the Observational
study. At entry into the CaD trial, participants’ demographic and medical history,
including heart failure, were assessed through administration of standardized
questionnaires. Participants were also invited to clinic centers for physical measurements
on blood pressure, anthropometry, and blood samples.
CaD participants were also contacted 4 weeks into the study to complete safety
and management issues on adherence, symptoms, and pill tolerance. This was then
repeated semi-annually as long as participants were on study pills. Routine follow-up and
data collection on CaD participants were carried out by the respective trial centers at
which they were recruited.
Safety and adherence concerns were regularly addressed during routine follow-up visits.
Participants were evaluated for safety concerns like renal calculi and constipation and
advised on how to manage the symptoms. Trained clinic staff also followed guidelines to
step-down study pills to about one pill a day when participants experienced these
symptoms or had difficulties taking their pills. Participants who developed medical
conditions such as hypercalcemia, renal calculi, need for hemodialysis or started taking
certain medications (listed on the CaD section study manual) were taken off of the study
pills without unblinding their study arm (153, 157). WHI staff recorded the dates and
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specific reasons for taking participants off study medications. Details about study
recruitment methods have already been published by Hays et al. (2003) (156).
3.5 Rationale for Analyzing the CaD Trial Data from the WHI Study
Even though controlled intervention studies are considered the gold standard for
testing causal inference, they are lengthy and expensive to conduct. The WHI CTs,
including CaD trial, are multi-million dollar well-conducted studies among
postmenopausal women. Hence, the WHI data is an ideal source to perform secondary
analysis of the effect of vitamin D (with calcium) supplementation on heart failure.
The WHI study is rich with a large nationally representative sample of
postmenopausal women for whom quality exposure and outcome data were recorded
(146). Specifically, vitamin D and calcium supplementation was randomized in a primary
prevention cohort with annual assessment CVD outcomes including hospitalization for
heart failure. This type of data is vital for epidemiological analysis with a focus on health
outcomes among populations. Epidemiological results from such a large study are likely
to be informative for public health policy initiatives.
Experienced scientists and well-trained staff from the clinical centers ensured the
execution and completion of such a study with high quality. This aspect of the WHI study
is not always guaranteed for many other large studies, let alone for individual or
institution based studies. Hence it is befitting to take advantage of this data for testing an
important hypothesis, effect of calcium plus vitamin D supplementation on heart failure,
with vital clinical and public health implications.
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The current secondary analysis on the WHI data may be limited by the
ascertainment of heart failure (HF) cases based on hospital discharge diagnosis. As
previously discussed in Chapter 1, hospital discharge diagnoses tend to overestimate HF
incidence among older populations (38). However, by readjudicating these hospital
discharge diagnosed HF cases, this misclassification bias is minimized (38). The WHI
readjudicated all the hospital discharge diagnosed HF cases.
3.6 The WHI Study Data Access
The WHI study data are not publicly accessible. However, individual
investigators are encouraged to collaborate with WHI Principal Investigators (PI) to
author manuscripts for publication in peer-reviewed scientific journals. Figure 1 in the
Appendix describes the steps involved with accessing the WHI study outlined on the
WHI website. For the present study, JoAnn Manson, MD, DrPH, a PI at the Women’s
Hospital, Havard Medical School, Boston, MA was identified as a collaborator and
sponsor. A proposal was developed in collaboration with my Doctoral dissertation
committee members to access the WHI data. The proposal was approved by the
Publications and Presentations (P&P) committee and WHI investigators nominated to
join me and my dissertation committee members to constitute a writing group. The letter
of approval from P&P along with the names and affiliations of the writing group can be
found in the Appendix.
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3.7 Assessment of Heart Failure and Other Covariates
3.7.1 Ascertainment of Heart Failure Cases
Trained staff abstracted medical records annually for self-report heart failure
hospitalization. The abstracted HF cases were then classified by an adjudication
committee of Physicians at local clinical sites using the criterion below:
Hospitalized HF only (HF requiring and/or occurring during hospitalization) requiring
physician diagnosis of new-onset or worsened congestive heart failure on the reported
hospital admission and 1 or more of the following 4 criteria:
1= HF diagnosed by physician and receiving medical treatment for HF
2= #1plus documentation in the current medical record of a history of an imaging
procedure showing impaired LV systolic or diastolic LV function
3=Pulmonary edema/ congestion on chest X-ray on the current admission
4=Dilated ventricle(s) or “poor” LV or RV function by ECHO, MUGA, RVG, or
other contrast ventriculography, or evidence of LV diastolic dysfunction
Description of the adjudication criterion for heart failure is found on Form 121 in the
Appendix.
3.7.2 Covariates and Effect Modifiers
Stratification of study sample by preexisting diagnosed cardiovascular risk factors of
heart failure
Diagnosed cardiovascular risk factors - hypertension, coronary heart disease, and
diabetes - have been consistently identified by different studies in diverse populations as
major risk factors for heart failure (48, 158-166). These factors are critical in the
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pathogenesis of heart failure and often heart failure diagnosis. This is why the American
College of Cardiology (ACC) classifies individuals with any of these risk factors with or
without structural abnormalities as stage A and B heart failure. Among females in the
Framingham study aged 40 -89 years, hypertension, myocardial infarction, angina, and
diabetes accounted for (population attributable risk) 59%, 13%, 5%, and 12% of heart
failure incidence respectively (167). However, among participants aged between 70 – 79
years old, systolic blood pressure (>140 mmHg), coronary heart disease, and fasting
blood glucose (> 125 mg/dL) accounted for 21.3%, 23.9% and 11.3% respectively in the
Caucasian population and 30.1%, 29.5% and 7.3% respectively in the African American
population (166). In the Cardiovascular Health Study (CHS), systolic blood pressure >
140 mmHg and coronary heart disease accounted for 12.8% and 13.1% of heart failure
incidence (48). These population attributable risk estimates suggest heart failure
incidence is relatively higher in subpopulations with diagnosed history of hypertension,
coronary heart diseases, and diabetes.
The CaD cohort was stratified into two groups; one consisted of participants who
reported any history of diagnosed hypertension, cardiovascular disease, coronary heart
disease/events, or diabetes, while the other group consisted of participants without any
history of a previous diagnosis of any of these heart failure risk factors. Given that low
serum 25(OH)D levels have been consistently associated with these same heart failure
risk factors (CVD, hypertension, and diabetes), supplementation with calcium plus
vitamin D may be associated with a relatively stronger effect estimates in this group
compared to those without these risk factors. We hypothesized that the association
between the vitamin D plus calcium supplementation and heart failure incidence is
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modified by these baseline cardiovascular risk factors of heart failure. This study aims to
estimate the effect of the intervention in the two groups classified based on the presence
or absence of these risk factors.
However, the practice of stratified or subgroup analyses in estimating the impact
of an intervention in randomized controlled trials has been debated in the scientific
community (168, 169). According to Lagakos (2003), subgroup analysis, when
performed and reported in a responsible manner, has great utility in clinical practice
(168). Conversely, when not appropriately conducted, subgroup analysis may be
misleading. To improve the translation of research results into clinical practice, Rothwell
et al. suggested subgroups be identified according to existing risk models used in clinical
practice (170). The cardiovascular risk factors used for grouping participants in this study
are components of existing heart failure risk models from the Framingham and the Health
ABC heart failure risk models (19, 171).
Description of diagnosed cardiovascular risk factors of heart failure
Hypertension: Two blood pressure (BP) measurements were taken at least 30 seconds
apart during enrollment and subsequent bi-annual visits. The average of the two BP
measurements at enrollment into the CaD trial was recorded and used in the definition of
hypertension in these analyses. History of hypertension or high BP diagnosis by a
physician was also ascertained during enrollment through questionnaires. Participants
were also asked if they were taking antihypertensive medication. Based on these data,
hypertension was defined as a self-report of a physician diagnosis of hypertension with or
without current use of antihypertensive medications or high BP (systolic BP >140 mmHg
67

and/or diastolic BP >90 mmHg) during enrollment into the CaD trial. This definition was
used to account for participants missing information for responses to the questions on
hypertension and for those who had elevated BP but had not being diagnosed. Based on
only participants’ responses, WHI estimated 21,772 (66.6%) as not hypertensive, 2,644
(8.1%) as untreated hypertensive, and 8,279 (25.3%) as treated hypertensives while 3,587
were missing information for this variable. Comparatively, our definition identified
21,484 (59.2%) as never hypertensive, 4,142 (11.4%) as treated hypertensives, and
10,656 (29.4%) as treated hypertensives.
Cardiovascular diseases (CVD): During enrollment into the CaD trial, and the WHI
study in general, participants were asked if a doctor has ever told them if they had heart
problems, problems with blood circulation or blood clots. A positive response (n = 4,749)
to this question was indicative of a previously diagnosed CVD. Missing responses (n =
3,654) were recoded as not having known CVD.
Coronary heart diseases (CHD): CHD was defined as a composite of self-reported
cardiac arrest, angina, coronary artery bypass graft surgery (CABG), and/or percutaneous
transluminal coronary angioplasty (PTCA). Below are the questions that were asked on
the questionnaire to ascertain these conditions or procedures. A positive response to at
least one of these indicted CHD.
“Please mark the conditions or procedures below that a doctor said you had”;
i. Cardiac arrest – “Cardiac arrest (where your heart stopped and needed to be restarted)”.
A total of 28,323 (78.1%) with missing responses to this question were recoded as not
having a history of cardiac arrest while only 93 responded positive.
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ii. CABG – “Heart bypass operation or coronary bypass surgery for blocked or clogged
arteries in your heart”. Only 232 participants provided a positive response while 436
(1.2%) participants had missing responses for this question and were recoded as never
had a CABG.
iii. PTCA – “Angioplasty of the coronary arteries (opening the arteries of the heart with a
balloon or other device, sometimes called a PTCA)”. Only 417 participants responded
with a positive answer while 430 (1.2%) had missing responses for this question and
were recoded as never had a PTCA.
iv. Angina – “Did a doctor ever say that you had angina (chest pains from a heart
problem)?”. There were 1,595 positive responses and 197 (0.5%) participants with
missing responses who were recoded as never had angina.
Diabetes: Diabetes was defined as a positive response to the question “Did a doctor ever
say that you had sugar diabetes or high blood sugar when you were not pregnant?” during
enrollment into the CaD trial and the WHI study in general. The 9 (0.02%) participants
with missing information were considered nondiabetic.
3.7.3 Other Potential Covariates
Risk factors of low vitamin D status and heart failure which were measured by the
CaD trial at baseline were evaluated as potential covariates for the association between
the intervention and heart failure incidence.
Demographic factors: Demographic factors included age (in years), race/ethnicity (NonHispanic white, Black/African American, Hispanic/Latina, and others), educational level,
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family income, and solar irradiance of region of residence in Langley units (172). The
solar irradiance of region of residence is a measure of the amount of solar energy per unit
area on the earth’s surface and is an important determinant of circulatory serum vitamin
D levels synthesized in the skin from UV radiations (68).
Lifestyle/behavioral factors: Lifestyle/behavioral risk factors of heart failure or low
vitamin D status include smoking status, alcohol consumption and physical activity (total
MET-hours/week). Self-reported personal consumption of calcium, vitamin D, and
multivitamin supplements and use of medication for hormone therapy in the past two
weeks and/or from prescribed medication were also included.
Physical measures: Physical measurements included as covariates were body mass index
(kg/m2), systolic and diastolic blood pressure (mmHg), and hypercholesterolemia
(physician diagnosis of high cholesterol requiring medication).
Dietary factors: Dietary intake factors were measured with food frequency questionnaires
(FFQ) administered during enrollment. Calcium consumption (mg/day) and vitamin D
(IU/day) from dietary sources only, were calculated and included in the analyses.
3.8 Sample Selection and Power Analyses
3.8.1 Sample
In addition to the exclusion criteria applied in the CaD study, prevalent heart
failure cases at enrollment and heart failure cases occurring within the first year of
randomization in the CaD trial were excluded (191 intervenion, 188 control) in this
analysis to create a primary prevention cohort of participants free from heart failure.
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Participants missing data for pertinent variables such as BMI, systolic and diastolic blood
pressures were also excluded. The details are presented in Table 3 and Figure 2. All
missing data for other categorical variables were assigned a value for the worse category
of the variable. These exclusion criteria reduced the study population to 35,113 (17,595
intervention and 17,518 placebo), a 3.2% reduction of the original population of 36,282.
Table 3
Frequency of missing values for select covariates by study allocation
Variables

Intervention,

Placebo,

Total

n (%)

n (%)

BMI

382 (49.6)

388 (50.4)

770

Systolic blood pressure

235 (49.4)

241 (50.6)

476

236 (49.4)

242 (50.6)

478

Diastolic blood
pressure

3.8.2 Power Analyses
The power and sample size calculator software PS (version 3.0.43) was used to
estimate the critical value of hazard ratios at the 0.05 alpha level for the two primary
hypotheses given the sample sizes (173). Below are the parameters that were
incorporated into the software to generate a range of detectable hazard ratios under
different conditions.
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a. Alpha, α – this specifies the level of type I error. A 0.05 alpha level was chosen to
allow only a 5% chance of wrongly rejecting the null hypothesis for the alternate when
the null is indeed true.
b. Power – this specifies the probability of correctly rejecting the null hypothesis when it
is false. An 80% power was specified to estimate the hazard ratio for the association
between the intervention and heart failure.
c. Sample size, N – three different sample sizes were specified. For the primary
hypothesis 1a, the sample size was the entire CaD cohort, N = 35,113. While for primary
hypothesis 1b, the sample sizes were specified for the two populations stratified by
baseline risk for heart failure. Hence, N = 18,097 for the low risk population and N =
17,016 for the low risk population.
d. Median survival time for the placebo group – the median survival time could not be
estimated from literature since there are no published data. It could not also be estimated
from Kaplan-Meier curves - given that this is a retrospective power analysis after the
CaD trial had completed – because more than 50% of the control group did not
experience a HF incidence at the end of the 9.8 year trial period. Hence, the median
survival time was estimated indirectly with equation (1).
Median survival =
where

(1)

= probability of survival at time =

;

T0 was specified as the total study time, 9.8 years
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e. The ratio of sample size of the placebo group to the intervention group. Table 4 and
Figures 6a, 6b, and 6c summarize the output from the software, PS.

Table 4
Computed critical hazard ratios for the three different populations from PS (version
3.0.43)

Sample size
(N)

Power, %

Alpha
(α)

Critical hazard ratio
for intervention
compared to placebo
(≤ )

Entire CaD cohort

35,113

80

0.05

0.82

No preexisting
diagnosed
cardiovascular risk
factors of HF

18,097

80

0.05

0.67

Preexisting diagnosed
cardiovascular risk
factors of HF

17,016

80

0.05

0.79
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Figure 6. Plot of statistical power with detectable hazard ratios for the entire CaD trial
cohort (n=35,113) analyzed.
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Figure 7. Plot of statistical power with detectable hazard ratios for subgroup of the CaD
trial participants without any preexisting CV risk factors at baseline (n= 18,097)
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Figure 8. Plot of statistical power with detectable hazard ratios for subgroup of the CaD
trial participants with at least one preexisting CV risk factor at baseline (n= 17,016).

3.9 Statistical Analysis
All statistical analyses were conducted with SAS (version 9.3). The intention-totreat (ITT) approach was adopted for all primary analyses to evaluate the effect of CaD
on the incidence of heart failure. ITT has been adopted and mandated by the Food and
Drug Administration (FDA) as the preferred approach for analyzing randomized clinical
trials (174). The American Statistical Association defined ITT as
“one which includes all randomized patients in the groups to which they were randomly
assigned, regardless of their compliance with the entry criteria, regardless of the
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treatment they actually received, and regardless of subsequent withdrawal from
treatment or deviation from the protocol” (175).
The advantages of adopting the ITT approach include the ability to detect small
effects because of enhanced statistical power and the ability to answer pragmatic
questions (176). The ITT approach is particularly beneficial for evaluating the efficacies
of treatments at the population level where not every individual prescribed a particular
treatment essentially adhere to their treatment regimen. However, the ITT is not ideal
when the goal of trial is to evaluate the effectiveness of a new treatment compared to a
placebo given all participants adhere to the treatment (177).
3.9.1 Descriptive Statistical Analyses
Formal tests (Chi-square or Fisher exact tests) of balance of individual categorical
covariates between the CaD and control arms were conducted. The Student’s t-test was
used to test the balance of continuous variables between the CaD and control arms. These
tests were repeated for the two trial cohorts created by stratifying the CaD trial population
based on the composite of baseline preexisting diagnosed cardiovascular risk factors of
HF.
3.9.2 Multivariable Analyses
Adopting an intention-to-treat (ITT) approach, the effect (hazard ratio) of calcium
plus vitamin D supplementation on the risk of hospitalization for heart failure was
assessed through Cox Proportional Hazard regression (CPH) models for the entire cohort
selected for this study. The Cox hazard regression model proposed by Sir David Cox
(1972) is used to estimate the effect of a variable or intervention under the assumption
that the hazard ratio, that is ratio of hazard functions between the strata of any categorical
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variable, is constant over time (178). This assumption is referred to as the proportionality
assumption. It is therefore important to ensure that the proportionality assumption is not
violated by the covariates included in the Cox hazard regression.
Graphical methods such as the Kaplan-Meier (KM) plots of cumulative incident
curves and the Schoenfeld residual plots were used to estimate the proportionality
assumption in this analysis. Additionally, a non-graphical or numerical method based on
the statistical significance of interaction terms between covariates and the time variable
estimated from a time-dependent Cox regression model was used. By the KM approach,
the assumption is not violated if the cumulative incidence curves are parallel over time or
without considerable overlap over time. The KM method is quite subjective since
investigators have different interpretations of what constitutes ‘parallel’. Schoenfeld
proposed a more objective graphical method to test the proportionality assumption by
plotting scaled Schoenfeld residuals that are independent of time against time in a
generalized linear regression model. If the slope of this plot is not zero, i.e. not parallel to
the horizontal line specified in the plot at zero on the vertical axis, then the
proportionality assumption is violated (179). In the time-dependent Cox regression
model, interaction product terms between individual covariates that need to be evaluated
for the proportionality assumption and time are added to the main effects of the Cox
regression model and their statistical significance evaluated individually and/or together.
If the interaction term with time for an individual covariate is < 0.05 (P-value) then that
covariate varies with time and hence violates the proportionality assumption (178).
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Association between vitamin D and calcium supplementation and heart failure incidence
Model 1a: An unadjusted CPH regression model was fitted to assess the effect of
randomization status on time-to-heart failure.
Model statement:
h(t|X) = h(t) exp(Xβ)

(2)

where X = randomization status (X = 1 for CaD, X = 0 for placebo)
t = time-to first heart failure event
The hazard ratio (HR) is then estimated as
HR(CaD:Placebo) = exp([CaD – Placebo] β) (3)
Model 1b: Same as Model 1a, but adjusted for HT and DM clinical trials by stratifying
the Cox CPH model on these trials. This allows the adjustment for these trials without
estimating their effect on time-to-heart failure.
h(t|X) = hz(t) exp(Xβ) (4)
where z = study arms of HT and DM clinical trials
In this stratified model the baseline hazard, hz(t), is allowed to vary for each
stratum of the HT and DM clinical trials.
Additionally, the effect of the intervention on time-to-heart failure was adjusted
for demographic (age, race, educational level, income, solar irradiance) and
lifestyle/behavioral (BMI and physical activity, self-reported total vitamin D and calcium
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intake at baseline) factors. These covariates were adjusted for because they are important
confounders known to be associated with heart failure and/or vitamin D status as
discussed in the literature review section of this study.
Model 1c: In building this model, baseline preexisting diagnosed cardiovascular risk
factors of heart failure (hypertension, CVD, CHD/coronary events, or diabetes) were
first added to Model 1b to evaluate their effect on the association between the
intervention and heart failure. Any change in the hazard ratio estimated in Model 1b
would be attributable to the presences of these risk factors. The rest of the covariates,
family history of CVD, alcohol intake, smoking status, hypercholesterolemia,
multivitamin use, and postmenopausal therapy medication use were then added to the
model.
Effect modification by preexisting baseline cardiovascular risk factors of heart failure
Statistical interaction between the intervention and a dichotomous variable
indicating the presence or absence of baseline preexisting diagnosed cardiovascular risk
factors for heart failure was assessed by including a product term between these two
factors in the CPH models described above. The P-value for this interaction term was
evaluated for statistical significance, P-interaction <0.05. For the multivariable adjusted
Models 1b and 1c, all covariates specified above but history of CVD, CHD, hypertension
and diabetes were included in the model because the baseline risk status was a composite
of these cardiometabolic diseases. If the product term was statistically significant, Pvalue < 0.05, stratum-specific hazard ratios were reported.
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Effect modification by baseline self-reported total vitamin D and calcium intakes
To evaluate the modification role of baseline total vitamin D intake on the
association between the intervention and heart failure, an interaction (product) term
between the two factors was added to the CPH regression models 1b (without total
vitamin D intake) and 1c (without total vitamin D intake). Since participants were
allowed to continue consumption of personal vitamin D supplements, baseline vitamin D
supplements intake was also evaluated as a potential effect modifier.
The role of total calcium intake at baseline as an effect modifier in the association
between the intervention and heart failure, the same methodological approach
implemented for vitamin D described above was adopted. Personal calcium supplement
intake (only) at baseline was also evaluated as a potential effect modifier.
3.10 Sensitivity Analyses
3.10.1 Per-protocol Analyses – 80% Adherence Rate
At the end of the CaD study 17,010 participants remained in the intervention arm
while 16,926 of the participants in the placebo arm remained; a 3.3% vs 3.4% loses
respectively. Additionally, only 57.6% (n = 20,227) of the participants adhered to at least
80% of the study medication; the placebo group had a slightly higher 80% adherence
rate, 58.8% (n = 10,296) compared to the intervention group, 56.5% (n = 9,936) (Table
5). Statistical analyses were then repeated using only the population with at least 80%
adherence rate to study medication. This method contrasts the intention-to-treat (ITT)
analyses and is referred to as the non intention-to-treat (non-ITT) analyses (176). In this
study, the per-protocol method of non-ITT analyses was adopted to test the effectiveness
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of calcium plus vitamin D as an intervention against heart failure. The disadvantage of
the non-ITT method is that it tends to be underpowered due to smaller sample sizes
and/or non-adherence to the intervention.

Table 5
Study protocol adherence rate
Adherence rate (%)
< 80
≥ 80

Randomization status, n (%)
Intervention
Control
7,662 (43.5)
7,228 (41.3)
9,936 (56.5)
10,296 (58.8)

Total, n (%)
14,890 (42.4)
20,232 (57.6)

3.10.2 Estimating Hazard Ratios Independent of Noncompliance to Study Protocol
by Inverse Probability of Censored Weights (IPCW) Method
The summary hazard ratios estimated in both ITT and per-protocol analyses described
above were dependent on the actual censoring distribution. A total of 1,177 (3.4%) of the
study population were lost to follow-up by the end of the trial (Figure 2); these
participants were right-censored in the CPH model, hence, making the estimated hazard
ratios dependent on the censoring. To estimate the hazard ratios with the CPH model
independent of censoring information, the inverse probability of censored weights
(IPCW) method suggested by Xu and O'Quigley (2000) was implemented (180, 181). In
addition to participants that were lost by the end of the trial, 88% (89.7% intervention,
86.7% placebo) of the population failed to completely (100%) adhere to the study
medication. The IPCW method has been proposed by Robins and Finkelstein (2000) to
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estimate treatment effects in case of noncompliance to treatment protocol in randomized
trials (182). The IPCW model was adjusted for some of the factors – age, education level,
use of personal calcium, vitamin D or multivitamin supplements, history of heart failure
risk factors, family history of CVD, and enrollment in other clinical trials - previously
reported as strong predictors of adherence to study medication in the CaD trial (183).
3.10.3 Interaction between Intervention and Baseline Serum 25(OH)D Levels
Serum 25-hydroxyvitamin D (25[OH]D) measurements were collected on 2,029
participants in the CaD trial as part of a nested case-control study to evaluate whether
pre-randomization serum 25(OH)D levels modified the association between the
intervention and risk of fractures (108). The DiaSorin Liason chemiluminescent
immunoassay system (Stillwater, Minn.) was used to measure serum 25(OH)D levels
(108). Among the sample selected for this study, 1,969 participants had measured serum
25(OH)D levels, among whom were 34 heart failure cases. A nested case-control was
also conducted, similar to the one designed by Jackson et. al. (2006), to evaluate whether
serum 25(OH)D modified the association between intervention and heart failure (108).
Owing to the very few heart failure cases with measured serum 25(OH)D measurements,
a 1:4 case to control matching was performed to create a total sample of 167 (34 cases,
133 controls). Matching was done on age (<60, 60 – 69, >69 years), race, and the solar
irradiance of participant’s region of residence since these are strong determinants of
serum 25(OH)D levels (68, 79, 80, 86, 88, 90, 91). A conditional logistic regression
model was used to evaluate statistical interaction between baseline serum 25(OH)D and
intervention status.
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CHAPTER 4

RESULTS
4.1 Characteristics of Participants during Randomization
The characteristics of study participants are summarized for the entire population
selected for our analyses and by baseline risk status for heart failure. These characteristics
were compared between the intervention and control groups.
4.1.1 Entire Study Population
Table 6 summarizes the distribution of sample characteristics at baseline by
randomization status. The study population consisted of 35,113 (17,595 CaD and 17,518
control) postmenopausal women with a mean age of 62.3 ± 6.9 (SD) currently residing in
the United States of America. Participants allocated to the intervention and placebo arms
had similar baseline socio-demographic, physical/lifestyle, and clinical factors based on
comparisons of both absolute frequencies and proportions (%) or means, as shown in
Table 6. The similarities between the study arms were confirmed by non-significant pvalues > 0.05 alpha-level obtained from chi-square and t-tests. Although efforts were
made to recruit a lot of women from minority racial/ethnic groups, the majority of
participants were Caucasian in both the intervention (83.0%) and control (83.7%) groups.
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Table 6
Distribution of Participants’ Characteristics by Treatment Group at Baseline - The
Vitamin D and calcium (CaD) Trial of the Women’s Health Initiative (WHI) Study, 1995
– 2005.

Baseline characteristics
Age (years)
49 - 59
60 – 69
70 – 81
Race/Ethnicity
White
Black
Hispanic
Other
Education
None/grade school
High school/some college
College
Beyond college
Income ($)
<25,000
25, 000 – 50,000
50,000 – 70,000
75,000 – 100,000
>100,000
Region by Solar Irradiance
475 – 500
400 – 430
375 – 380
350
300 – 325
High Cholesterol requiring pills ever
No
Yes
BMI (kg/m2)
18.00 – 24.99
25.00 – 29.99
>30.00
Alcohol intake
None
Past drinker
Less than 1 drink/month
Less than 7 drinks/week
More than 7 drinks/week

Vitamin D and calcium
(N=17,595)
% or
n or mean
± SD

Control (N=17,518)
n or mean

% or
± SD

6,542
7,997
3,056

37.2
45.5
17.4

6,503
7,978
3,037

37.1
45.5
17.3

14,609
1,587
754
645

83.0
9.0
4.3
3.7

14,667
1,531
687
633

83.7
8.7
3.9
3.6

377
10,837
1,804
4,557

2.1
61.6
10.3
26.0

348
10,833
1,785
4,552

2.0
61.8
10.2
26.0

3,699
7,862
3,339
1,405
1,290

21.0
44.7
19.0
8.0
7.3

3,673
7,815
3,318
1,450
1,262

21.0
44.6
18.9
8.3
7.2

3,742
2,917
1,928
3,796
5,212

21.3
16.6
11.0
21.6
29.6

3,712
2,910
1,930
3,773
5,193

21.2
16.6
11.0
21.5
29.6

15,679
1,916

89.1
10.9

15,643
1,875

89.3
10.7

4,925
6,257
6,413

28.0
35.6
36.5

5,062
6,193
6,263

28.9
35.5
35.8

1,943
3,033
2,451
8,316
1,852

11.0
17.2
13.9
47.3
10.5

1,945
3,086
2,414
8,224
1,849

11.1
17.6
13.8
47.0
10.6

85

Physical activity level (total METs/week)
Low
Moderate
High
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Smoking status
None
Past
Current
Multivitamin use
No
Yes
Daily calcium (supplements + diet), mg
Mean (SD)
< 800
800 – 1,200
> 1,200
Daily vitamin D (supplements + diet), IU
Mean (SD)
< 200
200 - 600
> 600
Ever received hormone replacement therapy
No
Yes
Hypertension
Never
Untreated
Treated
History of CVD
No
Yes
History Diabetes
No
Yes
History of CHD
No
Yes
Family history of CVD
No
Yes
Dietary modification trial assignment
Not randomized
Intervention
Control
Hormone therapy trial assignment
Not randomized
Estrogen alone intervention
Estrogen alone control
Estrogen + progesterone intervention
Estrogen + progesterone control

6,764
2,271
8,560

38.4
12.9
48.7

6,729
2,292
8,497

38.4
13.1
48.5

125.6
74.5

17.0
9.2

125.7
74.5

17.0
9.2

9,240
7,004
1,351

52.5
39.8
7.7

9,320
6,888
1,310

53.2
39.3
7.5

11,556
6,039

65.7
34.3

11,372
6,146

64.9
35.1

1142.0
9,201
3,493
4,904

668.8
52.3
19.6
27.9

1143.9
9,059
3,406
5,059

670.4
51.7
19.4
28.9

366.8
7,890
7,299
2,409

270.9
44.8
41.5
13.7

367.5
7,795
7,310
2,419

266.4
44.5
41.7
13.8

8,507
9,088

48.4
51.7

8,353
9,164

47.7
52.3

10,501
1,981
5,113

59.7
11.3
29.1

10,386
2,066
5,066

59.3
11.8
28.9

15,461
2,134

87.9
12.1

15,308
2,210

87.4
12.6

16,800
796

95.5
4.5

16,713
805

95.4
4.6

16,135
1,441

91.8
8.2

16,120
1,383

92.1
7.9

6,053
11,542

34.4
65.6

6,043
11,475

34.5
65.5

5,435
4,622
7,538

30.9
26.3
42.8

5,320
4,729
7,469

30.4
27.0
42.6

9,762
1,477
1,483
2,445
2,428

55.5
8.4
8.4
13.9
13.3

9,722
1,483
1,519
2,467
2,327

55.5
8.5
8.7
14.1
13.3
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Abbreviations: SD, standard deviation; BMI, body mass index; MET, metabolic equivalent of task; CVD,
cardiovascular disease; CHD, coronary heart disease.

4.1.2 Population stratified by baseline risk status for heart failure
The secondary hypothesis of this study was to evaluate and compare the effect of
CaD on baseline risk status for heart failure. The distribution of participant characteristics
by intervention status at baseline was evaluated for the high and low risk populations. Per
our definition, 17,016 participants (8,494 CaD and 8,522 placebo) reported at least one
preexisting diagnosed cardiovascular risk factor of heart failure (cardiovascular diseases,
coronary heart diseases, hypertension, or diabetes), while 18,079 participants (9,101 CaD
and 8,996 placebo) were free of these heart failure risk factors at baseline. The baseline
characteristics of participants free of preexisting diagnosed cardiovascular risk factors are
presented in Table 7. As observed in the sample selected for this analysis, the baseline
participants’ characteristics were balanced between the intervention and placebo groups
by randomization (Table 7) for this group. Similarly, all baseline characteristics of the
group with preexisting diagnosed cardiovascular risk factors of heart failure were
proportionally distributed between the intervention and control groups with the exception
of body mass index (BMI) (Table 8). A chi-squared p-value of 0.04 was observed for the
test of independence between the intervention and placebo groups by three categories of
BMI (18.00 – 24.99, 25.00 – 29.99, and >30.00). However, there was no significant
difference in the mean BMI between the intervention and control groups, 30.03 vs 30.06
kg/m2, P = 0.71 (Table 8).
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Table 7
Baseline Characteristics of Participants Without Preexisting Cardiovascular Risk Factors
of Heart Failure (N = 18,097) by Treatment Group - the Vitamin D and calcium (CaD)
Trial of thhe Women’s Health Initiative (WHI) Study, 1995 – 2005.

Baseline characteristics
Age (years)
49 - 59
60 – 69
70 – 81
Race/Ethnicity
White
Black
Hispanic
Other
Education
None/grade school
High school/some college
College
Beyond college
Income ($)
<25,000
25, 000 – 50,000
50,000 – 70,000
75,000 – 100,000
>100,000
Region by Solar Irradiance
475 – 500
400 – 430
375 – 380
350
300 – 325
High Cholesterol requiring pills ever
No
Yes
BMI (kg/m2)
18.00 – 24.99
25.00 – 29.99
>30.00
Alcohol intake
None
Past drinker
Less than 1 drink/month
Less than 7 drinks/week
More than 7 drinks/week
Physical activity level (total METs/week)

Vitamin D and calcium
(N = 9,101)
% or
n or mean
± SD

Control (N = 8,996)
n or
mean

% or
± SD

4,020
3,916
1,165

44.2
43.0
12.8

3,975
3,883
1,138

44.2
43.2
12.7

7,832
534
435
300

86.1
5.9
4.8
3.3

7,824
500
384
288

87.0
5.6
4.3
3.2

171
5,317
1,009
2,604

1.9
58.4
11.1
28.6

148
5,248
1,004
2,596

1.7
58.3
11.2
28.9

1,640
3,880
1,863
884
834

18.0
42.6
20.5
9.7
9.2

1,586
3,938
1,818
861
793

17.6
43.8
20.2
9.6
8.8

1,986
1,554
945
1,934
2,682

21.8
17.1
10.4
21.3
29.5

1,940
1,508
968
1,888
2,692

21.6
16.8
10.8
21.0
29.9

8,472
629

93.1
6.9

8,416
580

93.6
6.5

3,155
3,355
2,591

34.7
36.9
28.5

3,265
3,301
2,430

36.3
36.7
37.0

915
1,315
1,215
4,627
1,029

10.1
14.5
13.4
50.8
11.3

900
1,313
1,219
4,521
1,043

10.0
14.6
13.6
50.3
11.6
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Low
3,390
37.3
3,323
36.9
Moderate
1,103
12.2
1,152
12.8
High
4,608
50.6
4,521
50.3
Systolic blood pressure (mmHg)
117.6
11.9
117.5
11.9
Diastolic blood pressure (mmHg)
72.0
7.7
71.8
7.7
Smoking status
None
4,732
52.0
4,759
52.9
Past
3,162
39.7
3,525
39.2
Current
754
8.3
712
7.9
Multivitamin use
No
6,000
65.9
5,821
64.7
Yes
3,101
34.1
3,175
35.3
Daily calcium (supplements + diet), mg
Mean (SD)
1170.0
680.0
1166.5
660.3
< 800
4,664
51.2
4,526
50.3
800 – 1,200
1,805
19.8
1,748
19.4
> 1,200
2,634
28.9
2,725
30.3
Daily vitamin D (supplements + diet), IU
Mean (SD)
368.1
273.4
368.4
267.6
< 200
4,098
45.0
3,967
44.1
200 - 600
3,760
41.3
3,793
42.2
> 600
1,245
13.7
1,239
13.8
Ever received hormone replacement
therapy
No
4,336
47.6
4,175
46.4
Yes
4,765
52.4
4,821
53.6
Family history of CVD
No
3,506
38.5
3,446
38.3
Yes
5,595
61.5
5,550
61.7
Dietary modification trial assignment
Not randomized
2,887
31.7
2,756
30.6
Intervention
2,381
26.2
2,447
27.2
Control
3,833
42.1
3,793
42.2
Hormone therapy trial assignment
Not randomized
4,898
54.8
5,042
56.1
Estrogen alone intervention
638
7.0
648
7.2
Estrogen alone control
689
7.6
675
7.5
Estrogen + progesterone intervention
1,413
15.5
1,333
14.8
Estrogen + progesterone control
1,372
15.1
1,298
14.4
Abbreviations: SD, standard deviation; BMI, body mass index; MET, metabolic equivalent of task; CVD,
cardiovascular disease.
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Table 8
Baseline Characteristics of Participants with Preexisting Cardiovascular Risk Factors of
Heart Failure (N = 17,016) By Treatment Group - The Vitamin D and calcium (CaD)
Trial of the Women’s Health Initiative (WHI) Study, 1995 – 2005.

Baseline characteristics
Age (years)
49 - 59
60 – 69
70 – 81
Race/Ethnicity
White
Black
Hispanic
Other
Education
None/grade school
High school/some college
College
Beyond college
Income ($)
<25,000
25, 000 – 50,000
50,000 – 70,000
75,000 – 100,000
>100,000
Region by Solar Irradiance
475 – 500
400 – 430
375 – 380
350
300 – 325
High Cholesterol requiring pills ever
No
Yes
BMI (kg/m2)
Mean
18.00 – 24.99
25.00 – 29.99
>30.00
Alcohol intake
None
Past drinker
Less than 1 drink/month
Less than 7 drinks/week
More than 7 drinks/week

Vitamin D and calcium
(N=8,494)
% or
n or mean
± SD

Control
(N=8,522)
n or
% or
mean
± SD

2,522
4,081
1,891

29.7
48.1
22.3

2,528
4,095
1,899

29.7
48.1
22.3

6,777
1,053
319
345

80.0
12.4
3.8
4.1

6,843
1,031
303
345

80.3
12.1
3.6
4.1

206
5,520
795
1,973

2.4
65.0
9.4
23.2

200
5,585
781
1,956

2.4
65.5
9.2
23.0

2,059
3,982
1,476
521
456

24.2
46.9
17.4
6.1
5.4

2,087
3,877
1,500
589
469

24.5
45.5
17.6
6.9
5.5

1,756
1,363
983
1,862
2,530

20.7
16.1
11.6
21.9
29.8

1,772
1,402
962
1,885
2,501

20.8
16.5
11.3
22.1
29.4

7,207
1,287

84.9
15.1

7,227
1,295

84.8
15.2

30.07
1,770
2,902
3,822

6.14
20.8
34.2
45.0

30.03
1,797
2,892
3,833

6.20
21.1
33.9
45.0

1,028
1,718
1,236
3,689
823

12.1
20.2
14.6
43.4
9.7

1,045
1,773
1,195
3,703
806

12.3
20.8
14.0
43.5
9.5
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Physical activity level (total METs/week)
Low
3,374
39.7
3,406
40.0
Moderate
1,168
13.8
1,140
13.4
High
3,952
46.5
3,976
46.7
Systolic blood pressure (mmHg)
134.0
17.4
134.1
17.4
Diastolic blood pressure (mmHg)
77.3
9.8
77.2
9.8
Smoking status
None
4,508
53.1
4,561
53.5
Past
3,389
39.9
3,363
39.5
Current
597
7.0
598
7.0
Multivitamin use
No
5,556
65.4
5,551
65.1
Yes
2,938
34.6
2,971
34.9
Daily calcium (supplements + diet), mg
Mean (SD)
1112.7
655.8
1120.3
680.1
< 800
4,537
53.4
4,533
53.2
800 – 1,200
1,688
19.9
1,658
19.5
> 1,200
2,270
26.7
2,334
27.4
Daily vitamin D (supplements + diet), IU
Mean (SD)
365.4
268.3
366.6
265.1
< 200
3,792
44.6
3,828
44.9
200 - 600
3,539
41.7
3,517
41.3
> 600
1,164
13.7
1,180
13.8
Ever received hormone replacement
therapy
No
4,171
49.1
4,178
49.0
Yes
4,323
50.9
4,343
51.0
Family history of CVD
No
2,547
30.0
2,597
30.5
Yes
5,947
70.0
5,925
69.5
Dietary modification trial assignment
Not randomized
2,548
30.0
2,564
30.1
Intervention
2,241
26.4
2,282
26.8
Control
3,705
43.6
3,676
43.1
Hormone therapy trial assignment
Not randomized
4,773
56.2
4,680
54.9
Estrogen alone intervention
839
9.9
835
9.8
Estrogen alone control
794
9.4
844
9.9
Estrogen + progesterone intervention
1,032
12.2
1,134
13.3
Estrogen + progesterone control
1,056
12.4
1,029
12.1
Abbreviations: SD, standard deviation; BMI, body mass index; MET, metabolic equivalent of task; CVD,
cardiovascular disease.
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4.2 Estimation of Risk of Heart Failure (Hazard Ratios)
4.2.1. The Cox Proportional Hazard Regression Model and Test of the
Proportionality Assumption
The Kaplan-Meier curves for the intervention and control groups in Figure 7
appear to be parallel although they converge at two points before diverging after
approximately 6.5 years after randomization. It is therefore not clear whether the
proportionality assumption was violated or not. Hence, this proportionality assumption
was further evaluated with plots of Schoenfeld residuals obtained from a Cox regression
model containing all covariates (179). The Schoenfeld residual plots for the intervention
status (Figure 8) and the other variables confirmed that the proportionality assumption
was not violated because all the plotted curves were close to zero. A time-dependent Cox
regression model was also built to confirm that the proportionality assumption was met
by all variables. The major predictor, intervention status, and all other covariates neither
interacted with time individually or collectively, P-test of proportionality = 0.66. It was
assumed the proportionality assumption is not violated by the randomization status based
on results from both a graphical (Schoenfeld residual plots) and numerical (timedependent Cox regression) assessment methods.
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HR = 0.93
(95% CI: 0.80 -1.07)
P = 0.30

Figure 9. KM curves comparing the cumulative incidence of HF between the intervention
and placebo arms during follow-up period for the overall CaD cohort.
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Figure 10. Schoenfield residual curve to evaluate the proportional hazards assumption
between the intervention and placebo in the overall CaD cohort.

The proportionality assumption was also evaluated using Kaplan-Meier curves,
Schoenfeld residual plots, and time-dependent Cox regression model for populations
stratified on the presence or absence of baseline cardiovascular risk factors of heart
failure. Based on these methods, all variables, including the randomization status met the
proportionality assumption (P-test of proportionality = 0.95) for the population without
baseline cardiovascular risk factors of heart failure. Figures 9 and 10 are the KaplanMeier and Schoenfeld residual curves, respectively, testing the proportionality
assumption for the randomization status in this population. Even though the two
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cumulative incidence curves never converged or crossed, they begun to stay diverged
after approximately four years after randomization (Figure 8).

HR = 0.65
(95% CI: 0.46 - 0.91)
P = 0.02

Figure 11. KM curves comparing the cumulative incidence of HF between the
intervention and placebo arms during follow-up period for the subgroup of participants
without any preexisting CV risk factors at baseline.
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Figure 12. Schoenfield residual curve to evaluate the proportional hazards assumption
between the intervention and placebo in the subgroup of participants without any
preexisting CV risk factors at baseline.

However, in the population without preexisting cardiovascular risk factors of
heart failure at baseline, the cumulative incidence curves arms slightly crossed
intermittently at three points (Figure 11). Further evaluations by a Schoenfeld residual
plot shows a curve that is parallel to zero (Figure 12). Additionally, a time-dependent
Cox regression model also indicated that none of the covariates including the
randomization status interacted significantly with time (P-test of proportionality = 0.24).
Hence, the Cox proportional hazards model was used to estimate the hazard ratio
associated with CaD in this group.
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HR = 1.03
(95% CI: 0.87 – 1.23)
P = 0.73

Figure 13. KM curves comparing the cumulative incidence of HF between the
intervention and placebo arms during follow-up period for the subgroup of participants
with at least one preexisting CV risk factor at baseline.
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Figure 14. Schoenfield residual curve to evaluate the proportional hazards assumption
between the intervention and placebo in the subgroup of participants with at least one
preexisting CV risk factor at baseline.

4.2.2 Association between Calcium (1,000 Mg/Day) and Vitamin D (400 IU/Day)
Supplementation and Incidence of Heart Failure
Supplementation with vitamin D and calcium was associated with a nonstatistically significant 7.0% (HR, 0.93; 95% CI, 0.80 – 1.07, P = 0.30) reduction in the
risk of heart failure after approximately 10 years of follow-up (mean, 7.13 [SD, 1.33]
years) (Table 9). When the cumulative incidence curves for the intervention and placebo
groups in Figure 6 were compared by the Log-Rank test, the two curves were not
significantly different, P = 0.36. The risk only decreased slightly after adjusting
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minimally and fully for socio-demographic, physical/lifestyle, and comorbidity factors
(Table 9). Again, none of these hazard ratios were statistically significant.

99

Table 9
Association between calcium (1000 mg/day) and vitamin D (400 IU/day)
supplementation and incidence of heart failure, WHI study, 1995 – 2005.
Study arm

Heart failure
cases
N
Rate *

Hazard ratio (95% CI)
Unadjusted

Fully adjusted††

Placebo (n = 17,518)

339

27.1

Referent

Minimally
adjusted†
Referent

Intervention (n= 17,595)

318

25.2

0.93(0.80 – 1.07)

0.92(0.80 – 1.07)

0.92 (0.79 –1.06)

1
2.73(2.16 – 3.45)
6.10(4.77 – 7.80)

1
2.08 (1.63 – 2.64)
3.58 (2.75 – 4.66)

1
1.16(0.90 – 1.50)
0.89(0.58 – 1.39)
0.76(0.46 – 1.25)

1
0.91(0.70 – 1.19)
0.97(0.62 – 1.51)
0.61(0.36 – 1.03)

1
0.78(0.51 – 1.22)
0.64(0.38 – 1.08)
0.75(0.47 – 1.20)

1
0.81(0.52 – 1.26)
0.71(0.42 – 1.21)
0.81(0.51 – 1.31)

0.70(0.59 – 0.84)
0.52(0.40 – 0.68)
0.23(0.13 – 0.41)
0.49(0.31 – 0.79)

1
0.76(0.64 – 0.91)
0.59(0.45 – 0.78)
0.29(0.16 – 0.52)
0.62(0.39 – 1.04)

1
0.75(0.57 – 0.97)
1.13(0.86 – 1.50)
1.01(0.80 – 1.29)
0.75(0.60 – 0.95)

1
0.68 (0.52 – 0.90)
1.03 (0.78 – 1.36)
0.95 (0.75 – 1.20)
0.70 (0.55 – 0.88)

1
0.85(0.67 – 1.08)
0.72(0.61 – 0.86)

1
0.82(0.64 – 1.04)
0.73(0.61 – 0.86)

1
1.07(0.86 – 1.18)
1.86(1.51 – 2.29)

1
0.97(0.78 – 1.22)
1.37 (1.10 – 1.70)

1
1.03(0.75 – 1.41)
1.09(0.81 – 1.45)
1.10(0.81 – 1.49)

1
1.06(0.77 – 1.45)
1.08(0.81 – 1.45)
1.14(0.84 – 1.53)

1

1

Age (years)
49 - 59
60 – 69
70 – 81
Race/Ethnicity
White
Black
Hispanic
Other
Education
None/grade school
High school/college
College
Beyond college
Income ($)
<25,000
25, 000 – 50,000
50,000 – 70,000
75,000 – 100,000
>100,000
Region by Solar Irradiance
475 – 500
400 – 430
375 – 380
350
300 – 325
Physical activity level (total
METs/week)
Low
Moderate
High
BMI (kg/m2)
18.00 – 24.99
25.00 – 29.99
>30.00
Daily calcium (supplements
+ diet), mg
< 600
600 - 800
800 – 1,200
> 1,200
Daily vitamin D
(supplements + diet), IU
< 200

100

Referent

200 - 600
> 600
Ever received hormone
replacement therapy
No
Yes
High Cholesterol requiring
pills ever
No
Yes
Alcohol intake
None
Past drinker
Less than 1 drink/month
Less than 7 drinks/week
More than 7 drinks/week

1.07(0.86 – 1.34)
1.86(1.51 – 2.28)

1.00(0.77 – 1.29)
1.06(0.74 – 1.52)

1
0.87(0.74 – 1.02)

1
0.86(0.73 – 1.01)
1
1.03 (0.84 – 1.28)
1
1.13 (0.86 – 1.47)
0.93 (0.68 – 1.26)
0.99 (0.76 – 1.28)
0.74 (0.50 – 1.09)
1.02(1.06 – 1.03)

Systolic blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)
Smoking status
None
Past
Current
Multivitamin use
No
Yes
Family history of CVD
No
Yes
*
Rate/10,000 person years

0.98(0.97 – 0.99)

1
1.23(1.04 – 1.45)
1.58(1.17 – 2.12)
1
0.98(0.81 – 1.18)
1
1.31(1.10 – 1.57)

†

stratified on clinical trial (HT/DM) and adjusted for: age, race, educational level, income, solar irradiance, BMI,
physical activity, systolic blood pressure, diastolic blood pressure, calcium supplements intake, vitamin d supplement
intake, use of hormone replacement therapy
††

stratified on clinical trial (HT/DM) and adjusted for all variables in † in addition to cholesterol levels, smoking status,
alcohol intake, multivitamin use, family history of CVD, history of CVD, history of CHD, history of hypertension,
history of diabetes

4.2.3 Association between Calcium (1,000 Mg/Day) and Vitamin D (400 IU/Day)
Supplementation and Incidence of Heart Failure by Baseline Preexisting Diagnosed
Cardiovascular Risk Factors of HF
Effect modification by baseline preexisting diagnosed cardiovascular risk factors
of HF was evaluated by testing the statistical significance of a product (interaction) term
between the intervention and an indicator variable for the composite of these HF risk
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factors in both unadjusted and fully-adjusted Cox regression models. The interaction term
was statistically significant in both unadjusted (P-interaction = 0.02) and fully-adjusted
models (P-interaction = 0.02) indicating preexisting diagnosed cardiovascular risk factors
of HF modified the association between CaD and incidence of heart failure. A Log-Rank
test of the differences between the cumulative incidence rates of the intervention and
control group (Figure 9) was statistically significant (P = 0.01).
However, individually none of the baseline cardiovascular risk factors of heart
failure interacted significantly with the intervention - hypertension (P-interaction = 0.44),
CVD (P-interaction = 0.24), CHD/coronary events (P-interaction = 0.62), and diabetes
(P-interaction = 0.52). It is critical to note that there is considerable overlap of
participants with respect to these risk factors (Tables 10 and 11). Thus, given the
relatively small proportions of participants in each stratum (risk factor) and fewer heart
failure events, it makes statistical sense that significant interaction was not detected at an
alpha level < 0.05. It is also important not to misconstrue the lack of (partial) interaction
by the individual HF risk factors, even though collectively they interact significantly with
the intervention status, as a scenario of the Yule-Simpson paradox (184). A necessary
condition for the Yule-Simpson paradox to occur in a 2x2x2 contingency table is that all
three variables be dependent of each other (185). However, while these individual HF
risk factors are associated with their composite, they are not associated with the
randomization status because of the randomized study design nature (Table 6). Also, their
composite was not associated with the randomization status, χ 2 (0.49), P = 0.49. Hence it
is not likely the Yule-Simpson paradox was present in this data structure.
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Table 10
Overlap of baseline cardiovascular risk factors of heart failure
Baseline cardiovascular risk factors of heart failure
Hypertension
CVD
CHD
Diabetes

Frequency

%

No

No

No

No

18097

51.54

No

No

No

Yes

527

1.5

No

No

Yes

No

189

0.54

No

No

Yes

Yes

12

0.03

No

Yes

No

No

1616

4.6

No

Yes

No

Yes

65

0.19

No

Yes

Yes

No

346

0.99

No

Yes

Yes

Yes

35

0.1

Yes

No

No

No

10625

30.26

Yes

No

No

Yes

987

2.81

Yes

No

Yes

No

282

0.8

Yes

No

Yes

Yes

50

0.14

Yes

Yes

No

No

1438

4.1

Yes

Yes

No

Yes

158

0.45

Yes

Yes

Yes

No

554

1.58

Yes

Yes

Yes

Yes

132

0.38

Abbreviations: CVD, cardiovascular disease; CHD, coronary heart disease
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Table 11
Distribution of participants by minimum number of cardiovascular (CV) risk factors of
heart failure
Minimum

Randomization status

number of

(%)

CV risk

HF cases,
Intervention

Control

factors

N

N (%)

HR (95% CI)

None

18,106

140 (0.77)

51.7

51.4

0.66 (0.47 – 0.92)

One

12,957

263 (2.03)

37.0

36.8

1.07 (0.84 – 1.37)

Two

3,130

169 (5.40)

8.7

9.1

1.06 (0.79 – 1.43)

Three

797

70 (8.78)

2.2

2.3

0.82 (0.51 – 1.31)

Four

132

16 (12.12)

0.4

0.4

1.41 (0.52 – 3.77)
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Figure 15. KM curves comparing the cumulative incidence of heart failure between
populations stratified by the presence or absence of baseline cardiovascular risk factors of
heart failure.

Table 12 and Figure 14 report the effect of vitamin D and calcium on heart failure
stratified by individual baseline diagnosed cardiovascular risk factors of heart failure and
the composite of these factors. None of these individual baseline risk factors significantly
modified the effect of CaD on heart failure. However, when the hazard ratio for the
intervention was stratified by the composite of these cardiovascular risk factors, the
intervention was associated with a 35% reduced risk of HF, HR, 0.65; 95% CI, 0.46 –
0.87; P = 0.01, in the sample without preexisting cardiovascular risk factors of HF at
baseline. This association persisted after adjusting for a host of risk factors of heart
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failure and low vitamin D status, HR, 0.65; 95% CI, 0.46 – 0.92; P = 0.01. However, in
the sample with preexisting baseline cardiovascular risk factors, CaD did not affect risk
of HF in both unadjusted (HR, 1.03; 95% CI, 0.87 – 1.23; P = 0.73) and multivariableadjusted (HR, 1.02; 95% CI, 0.85 – 1.21; P = 0.87) models.
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Table 12
Association between calcium (1000 mg/day) and vitamin D (400 IU/day)
supplementation and heart failure stratified by baseline preexisting diagnosed
cardiovascular risk factors of heart failure, WHI study, 1995 – 2005.

Stratified by
baseline HF risk
factors

Intervention

Fully-adjusted†

Unadjusted

HF cases,
n (annualized %)

HR (95%CI)

P

HR (95%CI)

P

Control

Hypertension a
No (n= 20,887)
Yes (n= 14,226)

103 (0.14)
215 (0.43)

118 (0.16)
221 (0.44)

0.86 (0.66 – 1.12)
0.97 (0.80 – 1.17)

0.28
0.75

0.85 (0.65 – 1.11)
0.97 (0.80 – 1.17)

0.24
0.72

CVD b
No (n= 30,769)
Yes (n= 4,344)

175 (0.18)
102 (0.70)

199 (0.21)
97 (0.64)

0.88 (0.73 – 1.05)
1.07 (0.83 – 1.39)

0.14
0.59

0.87 (0.74 – 1.05)
1.10 (0.83 – 1.47)

0.16
0.60

CHD/coronary c
No (n= 33,513)
Yes (n=1,600)

266 (0.22)
52 (0.96)

287 (0.24)
52 (0.95)

0.92 (0.78 – 1.09)
1.01 (0.69 – 1.48)

0.32
0.96

0.91 (0.77 – 1.08)
1.01 (0.67 – 1.51)

0.27
0.97

Diabetes d
No (n= 33,147)
Yes (n=1,966)

249 (0.21)
69 (1.04)

272 (0.23)
67 (1.01)

0.91 (0.77 – 1.08)
1.02 (0.73 – 1.42)

0.27
0.92

0.91 (0.76 – 1.08)
1.01 (0.71 – 1.42)

0.27
0.98

55 (0.08)

84 (0.13)

0.65 (0.46 – 0.91)

0.01

0.65 (0.46 – 0.92)

0.01

263 (0.44)

255 (0.43)

1.03 (0.87 – 1.23)

0.73

1.02 (0.85 – 1.21)

0.87

CV risk factors e
None
(n=18,097)
Composite
(n=17,016)

Abbreviations: HF, heart failure; HR, hazard ratio; CI, confidence interval; P, p-value; CVD, cardiovascular disease;
CHD, coronary heart disease
†
stratified on clinical trial (HT/DM) and adjusted for: age, race, educational level, income, solar irradiance, BMI,
physical activity, systolic blood pressure, diastolic blood pressure, calcium supplements intake, vitamin d supplement
intake, use of hormone replacement therapy cholesterol levels, smoking status, alcohol intake, multivitamin use, and
family history of CVD
adjusted for history of CVD, history of CHD, history of diabetes and all variables in †
adjusted for history of hypertension, history of CHD, history of diabetes and all variables in †
c
adjusted for history of hypertension, history of CVD, history of diabetes and all variables in †
d
adjusted for history of hypertension, CVD, CHD and all variables in †
e
adjusted for all variables in † except history of hypertension, CVD, CHD, and diabetes
a

b
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Figure 16. Forest plot of hazard ratios for effect of vitamin D plus calcium
supplementation on heart failure.

4.2.4 Interaction between Intervention and Baseline Self-Reported Total (diet plus
supplements) Vitamin D and Calcium Intake
An interaction term between baseline total vitamin D intake (from diet and
supplements) and CaD was included in both unadjusted and fully-adjusted Cox
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regression models. These interaction terms were not statistically significant in either the
unadjusted (P-interaction = 0.26) or fully-adjusted (P-interaction = 0.22) models
suggesting total vitamin D intake did not modify the effect of CaD on the incidence of
HF in the entire cohort. We also tested whether only self-reported consumption of
personal vitamin D supplements (≤ 600 IU/day) modified the relationship between CaD
and incidence of HF. No statistically significant interaction effect was observed between
only self-reported vitamin D supplement intake and the intervention status (P-interaction
= 0.33) in the unadjusted model. Hazard ratios were estimated for groups stratified by
levels of self-reported total vitamin D intake and by only self-reported vitamin D
supplement intake (Table 13). Baseline total vitamin D intake did not also modify the
association between CaD and heart failure in groups stratified by baseline preexisting
cardiovascular risk factors (results not reported).
Multiplicative interaction between baseline total calcium intake (from diet and
supplements) and CaD was neither detected in unadjusted (P-interaction = 0.81) nor in
fully-adjusted models (P-interaction = 0.53). Baseline self-reported consumption of
calcium supplements (≤ 1,000 mg/day) alone did not also modify the association between
the intervention and heart failure (P-interaction = 0.14) in the unadjusted model.
Stratified hazard ratios by baseline total calcium intake and only self-reported calcium
supplement intakes are reported in Tables 13. Baseline total calcium intake did not also
modify the association between CaD and heart failure in groups stratified by baseline
preexisting cardiovascular risk factors (results not reported).
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Table 13
Association between calcium (1000 mg/day) plus vitamin D (400 IU/day)
supplementation and heart failure stratified by baseline vitamin D and calcium intakes,
WHI study, 1995 – 2005.

HF cases,
n (annualized %)

Baseline vitamin D and calcium
intakes

Intervention
Total vitamin D (IU/day) from diet and
supplements
<200 (n=15,756)
200–600(n=14,609)
≥600 (n=4,828)
Vitamin D supplements alone
No (n= 33,719)
Yes (n= 1,394)
Calcium (mg/day) from diet and
supplements
<800 (n=18,252)
800-1200 (n=6,899)
≥1,200 (n=9,962)

Control

142 (0.25)
128 (0.25)
48 (0.28)

154 (0.27)
150 (0.29)
35 (0.21)

309 (0.26)
9 (0.18)

325 (0.27)
14 (0.28)

173 (0.26)
66 (0.26)
79 (0.23)

182 (0.28)
69 (0.28)
88 (0.24)

Unadjusted
95% CI

0.91 (0.72 – 1.14)
0.85 (0.67 – 1.08)
1.35 (0.89 – 2.13)
0.94 (0.81 – 1.10)
0.62 (0.27 – 1.42)

0.93 (0.76 – 1.15)
0.94 (0.67 – 1.31)
0.92 (0.68 – 1.25)

Calcium supplements alone
No (n= 28,647)
270 (0.26)
274 (0.27)
0.98 (0.83 – 1.16)
Yes (n= 6,466)
48 (0.21)
65 (0.29)
0.72 (0.50 – 1.05)
Abbreviations: HF, heart failure; HR, hazard ratio; CI, confidence interval; P, P-value

P

0.42
0.17
0.15
0.47
0.26

0.50
0.70
0.60
0.82
0.09

4.3 Sensitivity Analyses
3.3.1 Per-protocol Analyses
During the intervention phase of the study, 57.6% (n = 20,227) of the participants
adhered to at least 80% of the study medication; the placebo group had a slightly higher
80% adherence rate, 58.8% (n = 10,293) compared to the intervention group, 56.5% (n =
9,934). Chi-square tests and t-tests of the distribution of baseline covariates between
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study arms indicated all covariates but smoking status (P = 0.05) were balance. However,
owing to the 42.4% reduction of the original study sample, only known demographic
(age, race, and educational status), lifestyle/physical (BMI, physical activity, systolic and
diastolic blood pressures), and cardiovascular risk factors (hypertension, CVD, CHD, and
diabetes) were included in multivariable Cox proportional hazard (CPH) regression
models. Smoking status was included in these models because it is an important risk
factor of HF and also for not being proportionally distributed between the intervention
and placebo groups. Hazard ratios were estimated for the entire study sample and also by
the two groups stratified by preexisting cardiovascular risk factors of HF. Similar to the
intention-to-treat analyses, CaD was associated with a 5% (HR = 0.95, 95% CI:0.75 –
1.19) and 42% (HR = 0.58, 95% CI:0.35 – 0.96) reduced risk of heart failure incidence in
the entire CaD cohort and in populations without preexisting baseline cardiovascular risk
factors of heart failure respectively (Table 14). Again, CaD was associated with a small
elevated risk of heart failure, 5% (HR = 1.05, 95% CI:0.81 – 1.37) in populations with
preexisting cardiovascular risk factors of heart failure (Table 13).
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Table 14
Association between calcium (1000 mg/day) and vitamin D (400 IU/day)
supplementation and heart failure among the study population with at least 80%
adherence to study medication, WHI study, 1995 – 2005.

Population

HF cases,
n (annualized %)
Intervention

HR (95% CI)

P

Pinteraction

Control

Entire CaD cohort
137 (0.19)
155 (0.21) 0.95 (0.75 – 1.19)
0.66
NA
(n=20,227)
Stratified by baseline
CV risk factors
None (n= 10,736)
24 (0.06)
41 (0.10)
0.58 (0.35 – 0.96)
0.03
Composite (n= 9,491)
113 (0.34)
114 (0.33) 1.05 (0.81 – 1.37)
0.69
<0.001
Abbreviations: CaD, calcium plus vitamin D trial; CV, cardiovascular; HF, heart failure; HR, hazard ratio;
CI, confidence interval; P, p-value for HR; P-interaction, p-value for interaction

4.3.2 Estimating Hazard Ratios Independent of Noncompliance to Study Protocol by
Inverse Probability of Censored Weights (IPCW) Method
The hazard ratios for the intervention estimated via the inverse probability of censored
weights (IPCW) method are reported in Table 15. The intervention was still observed to
be associated with reduced risk of heart failure in the CaD cohort and in populations
without preexisting baseline cardiovascular risk factors of heart failure. The intervention
was also still not associated with risk of heart failure in populations with preexisting
baseline cardiovascular risk factors of heart failure.
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Table 15
Estimated hazard ratios for the association between the intervention and risk of heart
failure independent of competing risks and noncompliance to study medication through
the inverse probability of censored weights method (IPCW).

HR (95% CI)
Population

Entire CaD cohort
(n=35,113)
Stratified by baseline CV
risk factors
None (n=18,097)
Composite (n = 17,016)

Unadjusted

P

Adjusted*

P

0.90 (0.71 – 1.15)

0.40

0.90 (0.71 – 1.15)

0.41

0.65 (0.35 - 1.21)
1.01 (0.81 – 1.26)

0.18
0.91

0.65 (0.34 – 1.23)
1.02 (0.82 – 1.26)

0.19
0.90

Abbreviations: CaD, calcium plus vitamin D trial; CV, cardiovascular; HF, heart failure; HR, hazard ratio;
CI, confidence interval; P, p-value for HR
*

adjusted for – age, education, use of personal calcium, vitamin D or multivitamin supplements, history of
heart failure risk factors (hypertension, CVD, CHD/coronary events, or diabetes), family history of CVD,
and enrollment in other clinical trials

4.3.4 Interaction between Intervention and Baseline Serum 25(OH)D Levels

The mean (±SD) baseline serum 25-hydroxyvitamin D concentrations were
similar between the intervention (17.3 ± 5.2 ng/mL) and placebo (16.7 ± 5.4 ng/mL)
groups, P = 0.44. Baseline 25-hydroxyvitamin D concentrations also did not significantly
interact with the intervention, P-interaction = 0.45.
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CHAPTER 5
DISCUSSION
5.1 Summary of Results
In the calcium plus vitamin D trial of the Women’s Health Initiative (WHI)
study, 318 of the 17,595 participants randomized to 1,000 mg calcium plus 400 IU
vitamin D3 per day (CaD) had a first (incident) hospitalization for heart failure (HF)
during an average follow-up time of 7.13 (SD, 1.33) years, while 339 of the 17,518
participants randomized to control had a first hospitalization for HF during the same
period. The crude annual hazard rate of HF in the control group was slightly higher than
that of the intervention group (27.1 vs. 25.2/10,000 person-years). CaD was associated
with a 7% reduced risk of HF which increased slightly to 8% after adjusting for HF
demographic, lifestyle/behavioral, and cardiovascular disease risk factors in
multivariable-adjusted Cox proportional hazards (CPH) regression models. With an a
priori power of 80% and an alpha level of 0.05, this study could not reject the null
hypothesis of no CaD effect for a hazard ratio (HR) of 0.93 (> the critical HR, 0.83)
among 35,113 postmenopausal women.
It was also observed that this association was modified by baseline risk status of
HF. When the study population was stratified by baseline preexisting diagnosed
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cardiovascular risk factors of HF, the intervention was significantly associated with a
35% risk reduction of HF among participants without preexisting diagnosed
cardiovascular risk factors of HF (hypertension, cardiovascular diseases, coronary heart
diseases/events, or diabetes) at baseline. On the other hand, the CaD was not associated
with risk of HF (HR = 1.02, 95% CI:0.85 – 1.21) among the participants with these risk
factors. These observed associations were neither modified by baseline total (diet and
supplements) calcium nor vitamin D intake. Even though participants were allowed to
continue consumption of personal calcium and/or vitamin D supplements, this did not
modify the association between the intervention and HF.
In sensitivity analyses, CaD still did not significantly reduce the risk of HF (HR
= 0.95, 95% CI:0.75 – 1.19) among the 20,227 (57.6% of the CaD cohort) participants
who were at least 80% adherent to the study protocol. When this group was stratified by
baseline diagnosed cardiovascular risk factors of HF, CaD was associated with a greater
and significant reduction of risk of HF, 43%, in the populations without preexisting
baseline diagnosed cardiovascular risk factors. The 80% adherence rate to study
medication did not change the association between the intervention and HF in
populations with preexisting baseline cardiovascular risk factors. The HRs estimated for
the association between the intervention and time-to-HF in the Cox proportional hazard
regression models in the main analyses remained unchanged even after adjusting for
noncompliance to study medication through the inverse probability of censoring weights
(IPCW) method. The effect of CaD on HF incidence estimated in the main and sensitivity
analyses were similar (in magnitude and statistical significance) to those estimated
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involving the entire original CaD cohort of 36,282 postmenopausal women (results not
shown).
These results suggest that while supplementation with calcium plus vitamin D did
not significantly reduce the risk of HF among all postmenopausal women, preexisting
cardiovascular risk factors of HF may modify this association. Hence, among participants
without any preexisting diagnosis of cardiovascular risk factors (hypertension, CVD,
CHD/events, or diabetes), CaD may cut the risk of HF by as much as 35% during an
average follow-up time of about 7 years. However, among postmenopausal women with
these risk factors, CaD may not be associated with any benefits for HF. This implies the
intervention may be a good primary preventive agent for HF since it was associated with
strong significant risk reduction in a group of women without stage A or B HF (those
without preexisting hypertension, CVD, coronary heart disease/events, or diabetes) but
not in those with stage A or B HF (those with preexisting hypertension, CVD, coronary
heart disease/events, or diabetes). There are no known existing data to compare the
findings of this study with. Plausible competing explanations for these findings are
discussed below.
5.1.1 Effect of Intervention in the Overall CaD Cohort
The lack of a strong statistically significant effect of the intervention in the overall
CaD cohort could be explained by the following theories:
1. Effect modification by baseline risk status: There was strong evidence of statistical
interaction between the baseline risk status and the intervention in both unadjusted and
multivariable adjusted CPH regression models. Qualitative interaction was observed
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because the intervention was associated with both significant and lower risk of HF in
women free of stage A or B HF but associated with a small elevated non-significant (2%,
P = 0.87) risk of HF in those with stage A or B HF. This suggests there is heterogeneity
in the effect of intervention on the risk of HF that is conditional on the existence of HF
precursors.
In combination and individually, preexisting diagnosed cardiovascular risk factors
at baseline were not confounders in this study. Individually, hypertension, CVD,
CHD/events, and diabetes were equally distributed between the intervention and control
groups (Table 6). When combined, they were still not significantly associated with the
randomization status, χ2 (0.49), P = 0.49. In order for the baseline risk status to be
considered a confounder it must be associated with both the outcome, HF, and the
exposure, randomization status. While the composite of these risk factors was associated
with HF, empirically it is not associated with the randomization.
Because the composite of preexisting diagnosed cardiovascular risk factors at
baseline was ruled out as a confounder and evidence suggests it was an effect modifier, it
is conceivable to observe both weak and nonsignificant hazard ratios associated with CaD
in the overall trial sample without stratification. In the presence of an effect modification,
the overall hazard ratio could be misleading and at best, noninformative.
2. Heart failure (HF) misclassification bias: The main event, heart failure incidence,
was based on self-reported hospitalization for HF. These reports were then adjudicated by
a trained physician committee at the local trial site. Even though the adjudication process
improves the validity of HF cases, asymptomatic HF patients and those with pre-clinical
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HF who were not yet being hospitalized for HF were not identified as cases. This
underestimation of HF incidence was likely to be equal in both study arms. That is, it is
unlikely there would be differential misclassification bias because both study participants
and the adjudication committee were blinded to the treatment allocation. The
underestimation of the incidence of HF in both study arms at equal proportions would
have attenuated the estimated hazard ratio which could explain the small risk reduction of
HF observed in this study.
3. Low vitamin D doses: The dosage of vitamin D in the CaD trial was previously
suggested by Hsia et al. (2007) as a plausible explanation for lack of lack of observed
strong association between the intervention and risk of cardiovascular events (129). The
current RDA for vitamin D is 600 IU/day for persons below 70 years old but the
intervention consisted of only 400 IU/day of vitamin D. While the revised RDA for
vitamin D, 600 IU/day, was aimed at raising serum 25(OH)D levels to optimize bone
health, it is unclear if such a dose might be adequate as an effective agent for a nonmusculoskeletal events such as HF. This subject will continue to be an open debate until
trials are designed to specifically test the dose-response relationship between vitamin D
and cardiovascular events in the general population.
4. Possible calcium antagonistic effects: The role of calcium in cardiovascular disease
and heart failure pathogeneses is still not clear. While there are no existing data on the
effect of calcium supplementation, with/without vitamin D, on HF, meta-analyses of
trials evaluating the effect of such an intervention on other cardiovascular diseases have
either reported elevated or no risk (5, 8, 186). Given these findings, it is plausible calcium
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did not play a significant role on the association observed between the intervention and
HF in the current study. However, if calcium supplementation is associated with elevated
risk of HF, then it is likely calcium had antagonistic effect against any potential
protective effect of vitamin D against HF, and hence pull the effect estimate towards the
null as observed, HR = 0.92. The CaD trial data does not support the theory that calcium
may be associated with elevated risk of HF. Neither total (diet plus supplements) calcium
nor calcium supplements (only personal supplements) modified the association between
the intervention and risk of HF in the analyses of the CaD trial data. Hence, it is likely the
observed small (8%) nonsignificant risk reduction of HF was not a result of combining
vitamin D with calcium for the intervention in the CaD trial. Hence, it is unlikely that
calcium attenuated the effect of vitamin D on HF in this study.
5.1.2 Effect of the Intervention in Populations with Preexisting Baseline
Cardiovascular Risk Factors of Heart Failure
Contrary to the second primary hypothesis of this study, CaD will be associated
with stronger lower risk of HF in preexisting baseline cardiovascular risk factors, the
association of the intervention with risk of HF was null and nonsignificant in this group.
There was also no evidence to reject the null hypothesis in favor of our alternate
hypothesis. While this finding may also appear to contradict existing literature that
support a beneficial role for vitamin D in heart failure prevention, several reasons could
help explain the finding of this study.
One plausible explanation for the lack of an association between CaD and risk of
HF in this population is that they were more predisposed to developing heart failure
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compared to those without the cardiovascular risk factors of heart failure. This could have
diminished any benefit that might have been achieved towards HF prevention. Our data
suggests that the stage A or B HF group indeed might be of poorer health status
compared to those free of stage A or B HF with regards to heart failure incidence. Other
factors associated with poor health and risk of HF such as older age, educational status,
obesity, and hypercholesterolemia were significantly higher in the stage A or B HF group
to their counterparts (Table 16). The notable exception is smoking (current or past), a risk
factor of HF, which was rather higher in those without stage A or B HF – perhaps, those
in stage A or B HF group were asked by their health care givers to quit smoking owing to
their health status.
Mortality was significantly higher in the stage A or B HF group (Table 16). This
is another indication of the relatively poorer health status of this population compared to
those free of stage A or B HF. Death could therefore have been a competing risk event in
the estimation of hazard ratios (HRs) for the intervention from the Cox proportional
hazard regression models. That is, death as a competing risk prevents the incidence of
heart failure which masks the effect of the intervention on heart failure. However, in the
stage A or B HF group, there was not a significant difference (P = 0.09) in mortality
between the intervention (n = 464, 47.3%) and control (n = 517, 52.7%) groups.
Additionally, the HRs did not change when estimated independent of competing events
and noncompliance to study protocol through the inverse probability of censoring
weights (IPCW) method; the HR associated with the intervention increased marginally
from 1.02 to 1.05 (Table 15).
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Table 16
Distribution of selected baseline covariates by the presence and absence of baseline
cardiovascular risk factors of heart failure
Risk factors

Age (mean ± SD)
50 – 59
60 – 69
70 - 81
Smoking
Never
Past
Current
BMI (kg/m2)
<24.9
25.0 – 29.9
≥30.0
Education
None/grade school
High school/some
college
College
Beyond college
Vitamin D supplements
Calcium supplements
Multivitamin
supplements
Hypercholesterolemia
Adherence rate
Mortality

Preexisting baseline cardiovascular risk factors
of heart failure
Absent
Present
61.1 (6.7)
63.6 (6.9)
7,995 (44.2)
5,050 (48.1)
7,799 (43.1)
8,176 (48.1)
2,303 (12.7)
3,790 (22.3)

P-value

<0.001

9,491 (52.5)
7,140 (39.5)
1,466 (8.1)

9,069 (53.3)
6,752 (39.7)
1,195 (7.0)

< 0.001

6,420 (35.5)
6,656 (36.8)
5,021 (27.7)

3,567 (21.0)
5,794 (34.1)
7,655 (45.0)

<0.001

319 (1.8)
10,565 (58.4)
2,013 (11.1)
5,200 (28.7)

406 (2.4)
11,105 (65.3)
1,576 (9.3)
3,929 (23.1)

<0.001

7,563 (41.8)
8,793 (48.6)
6,276 (34.7)

6,652 (39.1)
7,680 (45.1)
5,909 (34.7)

< 0.001
< 0.001
0.93

1,209 (6.7)
7,361 (40.7)
432 (2.4)

2,582 (15.2)
7,525 (44.2)
981 (5.8)

<0.001
<0.001
<0.001
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It is also plausible that medical therapy for treatment of the cardiovascular risk
factors in the stage A or B HF group might have reduced the incidence of HF thereby
rendering the intervention impotent. Interaction between the intervention and
cardiovascular disease medications (ACE inhibitors, statins, beta blockers, and calcium
blockers) was evaluated in sensitivity analysis (Supplementary tables). None of these
medications, individually or their composite, interacted significantly with the intervention
at statistical significant alpha level of 0.10. However, in the group free of stage A or B
HF there was significant interaction between the use of ACE inhibitors (n = 1,006; 5.4%)
and the intervention, P-interaction = 0.05. The intervention was associated with about a
2-fold increased significant risk of HF (HR = 1.94, 95% CI:1.32 – 2.84) among users of
ACE inhibitors but non-significant lower risk (HR = 0.93, 95% CI:0.50 – 1.72) among
non-users in group free of stage A or B HF. In the group with stage A or B HF, only the
use of calcium blockers (n = 5,691; 32.6%) had a significant interaction effect on the
intervention, P-interaction = 0.09. The effects of the intervention stratified by use of
calcium blockers were not statistically significant, however, a lower risk was observed
among non-users (HR = 0.83, 95% CI:0.66 – 1.04) compared to an elevated risk among
users (HR = 1.11, 95% CI:0.87 – 1.38).
It appears therapeutic use of ACE inhibitors in the group of women without
preexisting hypertension, CVD, CHD/events or diabetes modified the effect of CaD on
HF. This suggests that the therapeutic use of ACE inhibitors for other medical conditions
besides hypertension, CVD, CHD/events or diabetes helps reduce the risk of HF among
women taking CaD supplements. Calcium channel blockers, another high blood pressure
control medication, also appeared to modify the relationship between CaD and HF; CaD
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increased the risk of HF among users of calcium channel blockers. This suggests calcium
channels blockers may have an antagonistic effect on the association between CaD and
HF since a lower risk was observed in non-users but not in users. It could also mean that
calcium channels blockers do not have any antagonistic effect and that the elevated HF
risk observed is a result of the effect of the advanced stage of the conditions that are
being treated with calcium channel blockers. Based on these results it is unclear what role
cardiovascular therapy played in the null effect observed for the association between CaD
and HF.
In the absence of confounders, especially those not observed and/or controlled for
in the analyses, the findings in the stage A or B HF group suggests CaD was not an
effective secondary prevention therapy in among women with stage A or B heart failure.
However, CaD may still be associated with HF through a direct pathway as suggested by
data from women without stage A or B HF.
5.1.3 Effect of the Intervention in Populations without Preexisting Baseline
Cardiovascular Risk Factors of Heart Failure
The intervention was associated with a lower risk of HF, compared to placebo, in
both unadjusted and multivariable-adjusted Cox proportional hazard regression models in
the primary as well as sensitivity analyses in a population of postmenopausal women free
of prevalent HF and the major HF cardiovascular risk factors. Calcium plus vitamin D
supplementation was associated with a 35% HF risk reduction during an average followup period of 7.13 (SD, 1.33) years. Several competing explanations for this finding are
discussed.
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Biological explanations for this association relate to the role of vitamin D in the
pathogenesis of HF. While data from animal models suggest a direct causal pathway
between low vitamin D and HF, both animal and human studies also suggest an indirect
causal pathway model involving the up-regulation of the renin-angiotensin-aldesterone
system (RAAS), and hyperparathyroidism (110).
Data from animal models suggest vitamin D may regulate cardiac functions at
least partially via interaction with the vitamin D receptor (VDR) in cardiac myocytes (10,
119). Through a receptor-mediated mechanism, 1,25(OH)2D regulates intracellular
calcium homeostasis and calcium ion uptake in ventricular cardiac muscle cells to modify
cardiac contractility (120). While this phenomenon at the cellular level could not be
observed in the CaD trial or other human studies, it is plausible that the reduced risk of
HF associated with calcium plus vitamin D supplementation was achieved in this manner.
The intermediate model involving the up-regulation of RAAS has been observed
in both human and animal studies. The renin-angiotensin-aldosterone system (RAAS)
plays a major role in HF pathogenesis by regulating blood pressure, cardiac contractility,
electrolyte homeostasis, and eccentric hypertrophy of the myocardium (111, 112). It has
been demonstrated that mice without the vitamin D receptor (VDR) developed high blood
pressure, cardiac enlargement, and experience increased activation of the RAAS (113).
The activation of RAAS by low vitamin D status has recently been suggested in humans
based on observational studies (114, 115). However, a meta-analysis of 10 trials,
including the WHI’s vitamin D and calcium trial, did not show an association between
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vitamin D (alone or with calcium) supplementation and reduction in either systolic nor
diastolic blood pressures (6).
Hyperparathyroidism has also been postulated as an intermediate process in the
vitamin D-heart failure pathophysiology. Data from end-stage renal disease (ESRD)
patients suggests secondary hyperparathyroidism and elevated parathyroid hormone
(PTH) levels were associated with low vitamin D levels, caused by failure of the kidneys
to convert 25(OH)D to the metabolic form of 1,25(OH)D2 (10, 15-17). Chronic exposure
to PTH has been reported to be associated with poor myocardial structure and functioning
as well as elevated blood pressure and accelerated atherosclerosis. Excess PTH may also
lead to cardiomyocyte hypertrophy, an important risk factor for HF, especially among
hemodialysis patients (13, 15, 118). Therefore, supplementation with both vitamin D and
calcium could have prevented or mitigated hyperparathyroidism and subsequently
reduced HF incidence in the intervention group.
Another indirect causal pathway involves pancreatic beta cell dysfunction and
insulin resistance both of which are major risk factors of type 2 diabetes and the
metabolic syndrome. Both type 2 diabetes and the metabolic syndrome can lead to heart
failure (110). Vitamin D was observed to induce insulin secretion by the pancreas in
animal models (187). Hyperparathyoridsm have also been implicated in pancreatic beta
cell dysfunction and disruption of normal insulin secretion in rats (188). However,
vitamin D supplementation, with or without calcium, had no significant effect on fasting
plasma glucose level in populations with normal glucose tolerance at baseline in a metaanalysis of 5 trials (6). Additionally, in the WHI CaD trial, calcium plus vitamin D
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supplementation was not associated with the incidence of type 2 diabetes (189). It is
therefore not clear if the lower risk reduction of heart failure associated with calcium plus
vitamin D supplementation in our study involved this pathway, given these equivocal
findings.
The data presented above suggests the association between vitamin D plus
calcium supplementation and heart failure incidence may be a biological one.
Specifically, a direct pathophysiological between vitamin D and heart failure
pathogenesis appears to be supported by this study. Evidence from this study is not
sufficient to support the indirect pathophysiological model because of the lack of
association between CaD and heart failure incidence among postmenopausal women with
preexisting diagnosed cardiovascular risk factors of heart failure. The randomized study
design also allows us to establish temporality for this association between CaD and
incidence of heart failure, that is the potential putative factor, CaD supplementation,
precedes the incidence of heart failure. The statistically and clinically significant effect of
CaD on heart failure incidence in this population in both intention-to-treat and perprotocol analyses implies the intervention was both effective and efficacious.
5.2 Limitations
Study limitations are inherent in the original study design of the vitamin D and
calcium (CaD) trial. First, As a result of combining calcium with vitamin D as the
intervention, it is not clear whether the observed associations are due to either just one of
these chemical agents or both. Second, the trial was limited to postmenopausal women,
50 – 81 years old, which limits the ability to generalize the findings to younger females
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and males of all ages in the general population. Third, heart failure (HF) incidence was
based on the participant’s self report of being hospitalized for HF would have probably
underestimated the true incidence since participants with pre-clinical or asymptomatic HF
would not have been captured. However, this type of bias is expected to be nondifferential and if eliminated, would result in stronger effect estimates away from the
null. Lastly, for ethical reasons, participants were allowed to continue consumption of
both vitamin D and calcium supplements within the recommended dietary allowance
guidelines by the Institute of Medicine. However, neither baseline total (diet plus
supplements) calcium nor vitamin D intake modified the association between the
intervention and risk of HF. Baseline vitamin D and calcium supplements (only) intake
did not also modify the association between the intervention and risk of HF.
5.3 Strengths
This study contributes to the growing literature on the association between vitamin
D and incidence of heart failure (HF). This study is the first to demonstrate a significant
HF risk reduction associated with vitamin D, with calcium, supplementation among
postmenopausal women. The study also demonstrated that while vitamin D, with
calcium, supplementation may be associated with reduced risk of HF, this association
may only exist among postmenopausal women without preexisting diagnoses of
cardiovascular risk factors of HF (hypertension, cardiovascular diseases, coronary heart
diseases/events, or diabetes). The study had adequate statistical power to detect the
observed hazard ratio of 0.65 associated with CaD in the sample of postmenopausal
women free of HF and diagnoses of cardiovascular risk factors at baseline. The study was
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randomized to minimize confounding effects by other covariates associated with both
vitamin D status and HF. All selected covariates were balanced between study arms for
the entire CaD cohort and the stratified cohort based on preexisting major HF
cardiovascular risk factors at baseline.
5.4 Public Health Implications
These findings, if confirmed in other research, have important public health and
clinical implications. Findings from this study suggests that the risk of heart failure, a
major public health concern, can be reduced by a simple and inexpensive intervention of
calcium plus vitamin D supplementation among postmenopausal women who do not have
preexisting major heart failure risk factors such as hypertension, cardiovascular diseases,
coronary heart diseases/events, or diabetes. In this population, supplementation with
calcium plus vitamin D for a period of about 7.5 years may prevent one heart failure
event among approximately 250 individuals (Figure 14).
Specifically, this low-cost (about $35.00 annually) public health prevention
strategy for heart failure which costs about $17,654.00 to $25,325.00 per hospitalization
could be a very cost-effective one (190, 191). To illustrate how much healthcare cost for
treatment of heart that can be saved with vitamin D plus calcium supplements, it costs
about $65,625.00 (=250[NNT] x 7.5 [years of supplementation] x $35.00[cost of
supplements/year]) to prevent one heart failure from occurring in a postmenopausal
woman without CV risk factors of HF a 7.5 year period through vitamin D plus calcium
supplementation. However, if this individual woman had developed HF, it would have
cost about $132,405.00 to $189,937.50 to treat her in the same period of time, 7.5 years,
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assuming 1 hospitalization per year. The trade off is clear, about $66,780 to $124,312.50
could be saved in the cost of hospitalization of heart failure alone for this woman.
In addition to the reduction in cost of hospitalization, other healthcare costs due to
the treatment and management of heart failure such as medication, home healthcare,
physicians, and nursing home care could be saved with this inexpensive intervention.
Additionally, this inexpensive intervention could also save this woman from the
enormous and invaluable physical and emotional burden of heart failure the ultimately
prevented a premature death from heart failure.

Number Needed to Treat (NTT)

Number Needed to Treat (NTT) after Randomization in Populations
without Preexisting Cardiovascular Risk Factors of Heart Failure
3500
3000
2500
2000
1500
1000
500
0

0

1

2

3
4
5
6
Time Since Randomization (years)

7

8

9

Figure 17. Plot of number needed to treat by vitamin D and calcium supplementation in
populations without preexisting cardiovascular risk factors of heart failure.
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CONCLUSION
Calcium (1000 mg/day) plus vitamin D (400 IU/day) supplementation was
associated with a nonsignificant reduction of risk of heart failure among postmenopausal
women enrolled in the vitamin D and calcium trial (CaD) of the Women’s Health
Initiative (WHI) study during an average follow-up period of 7 years. However, this
association was modified by the presence of preexisting diagnosed cardiovascular risk
factors of heart failure (hypertension, cardiovascular diseases, coronary heart
disease/events, or diabetes) at baseline. CaD was associated with a 35% statistically
significant risk reduction of heart failure among the sample without preexisting
diagnosed cardiovascular risk factors of heart failure. Among women with these
cardiovascular risk factors at baseline, CaD was not associated with risk of heart failure.
While the analyses confirmed one of our study primary hypotheses, that baseline risk
status of heart failure modified the association between the intervention and risk of heart
failure, there was not strong evidence to reject the null hypothesis that the intervention
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was not associated with risk of heart failure in the overall CaD cohort. Additionally,
contrary to the study’s hypothesis that the intervention was associated with a stronger risk
reduction of heart failure in the population with preexisting baseline cardiovascular risk
factors of heart failure than in the population without these risk factors, stronger risk
reduction was rather observed in the latter population. Future studies are warranted to
replicate our findings.
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RECOMMENDATIONS
Future intervention trials of vitamin D supplements, both with and without
calcium, should be conducted in the general adult male and female populations. The
population heterogeneity of baseline risk status for heart failure should be considered
when designing future trials. It will also be important to design future trials in a manner
that will allow investigators to estimate the association between heart failure incidence
and vitamin D alone, calcium alone, or their combination. A 2 x 2 multifactorial trial
design calcium plus vitamin D, calcium alone, vitamin D alone, and placebo is one
design that will help future investigators estimate the association between these vitamins
and heart failure. It may also be important to use dose of vitamin D of at least 600 IU/day
in future trials, according to the current IOM’s recommendation. Above all, future studies
should pre-specify heart failure as a primary outcome of interest and explicitly define it’s
ascertainment criteria. A central adjudication committee should always be used to certify
all self-reported cases of hospitalization for heart failure as incident heart failure cases.
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APPENDIX
Table 1
Heart failure assessment criteria
Criterion
Framingham

Major Parameters/characteristics of criterion


Paroxysmal nocturnal dyspnea



Neck vein distention



Rales



Radiographic cardiomegaly (increasing heart size on chest
radiography)



Acute pulmonary edema



S3 gallop



Increased central venous pressure (>16 cm H2O at right
atrium)



Hepatojugular reflux



Weight loss >4.5 kg in 5 days in response to treatment

Minor criteria:


Bilateral ankle edema

151



Nocturnal cough



Dyspnea on ordinary exertion



Hepatomegaly



Pleural effusion



Decrease in vital capacity by one third from maximum
recorded



Tachycardia (heart rate>120 beats/min.)

152

153

Boston

Category I: history


Rest dyspnea



Orthopnea



Paroxysmal nocturnal dyspnea



Dyspnea while walking on level area



Dyspnea while climbing

Category II: physical examination


Heart rate abnormality (1 point if 91 to 110 beats per minute; 2
points if more than 110 beats per minute)



Jugular venous elevation (2 points if greater than 6 cm H 2O; 3
points if greater than 6 cm H2O plus hepatomegaly or edema)



Lung crackles (1 point if basilar; 2 points if more than basilar)



Wheezing



Third heart sound

Category III: chest radiography


Alveolar pulmonary edema



Interstitial pulmonary edema



Bilateral pleural effusion



Cardiothoracic ratio greater than 0.50



Upper zone flow redistribution
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Table 2
Interaction between intervention and use of cardiovascular medication

Medication
ACE inhibitors
Betablockers
Antilipids
Calcium blockers
Composite
CV: cardiovascular

P-value for interaction between intervention and use of
cardiovascular medication
Overall cohort
Free of CV risk
Preexisting CV
factors
risk factors
0.18
0.05
0.98
0.83
0.55
0.78
0.34
0.88
0.11
0.26
0.40
0.09
0.20
0.14
0.74
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